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Abstract
Through the use of developmental and knock out studies Mig-6 has been shown to have a
role in development. It has also been shown to be a tumour suppressor gene. Little work has
been done as yet looking at its role in the adult.
This study examined the role of Mig-6 in the lung with the ultimate goal being to determine if
the pulmonary phenotype due to Mig-6 ablation is due to a developmental programming or
loss of function in the adult. This was investigated in two ways.
1. To investigate if knocking out Mig-6 in adult lung has an effect on lung function
2. Investigate the role of Mig-6 in lung epithelial cells by RNAi (Investigation of the
Role of Mig-6 in Pulmonary Epithelial Cells and Vascular Cells In Vitro).
Knocking out Mig-6 in the adult mice showed no difference in epithelial markers and after
staining morphology and airway size were found to be normal. This would seem to indicate
that the Mig-6 phenotype is due to altered development of the lungs during the neonatal
period and not due to a loss of function in the adult.
From the cell work we observed differences in the effect on epithelial cells vs. endothelial
cells when Mig-6 was knocked out. The epithelial cells showed an increased number of
viable cells present after knocking out Mig-6 while the number of viable cells was decreased
in the endothelial cells. This would indicate that knocking out Mig-6 in epithelial cells causes
increased proliferation but in endothelial cells causes apoptosis.
Conclusions: Ablation of Mig-6 leads to increased proliferation in epithelial cells (and
apoptosis in endothelial cells) but knocking it out in the adult stage has a mild effect on lung
phenotype
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1. Introduction
Mig-6 is an immediate early response gene which is transcriptionally induced by a number of
factors including growth factors, stress, cytokines and the Ras oncoprotein (1,2,3). This gene
in only present in higher eukaryotes (4) and can be rapidly induced allowing it to potentially
involved in early regulation of cellular responses (4). Mig-6 has been shown to be involved in
the EGF signalling pathway (4) and has been proposed to be involved in the HGF signalling
pathway as a negative regulator. It has previously shown in our laboratory that Mig-6 levels
in the lung change throughout development and that Mig-6 has a developmental role (5) so
the overall aim of our work was to investigate whether Mig-6 also played a role post-natally.
A Mig-6 knockout mouse (Mig-6-/-) has been developed by the DeMayo lab at Baylor
College of Medicine where Mig-6 has been knocked out at the germline level which has
enabled us to look at what occurs during development in the absence of Mig-6 (6). The
embryo lethal phenotype and multi-tissue carcinogenesis of the Mig-6 null allele make it
difficult to investigate the impact of ablation of Mig-6 on specific tissues and at specific time
points during development. A conditional knockout would overcome this.
Our lab developed an inducible ablation model by crossing Rosa26-Cre-ERT2 mice with
Mig-6flox/flox mice providing us with a population of Cre positive mice in addition to Cre
negative mice. Administration of Tamoxifen to Cre positive mice would induce ablation of
Mig-6 and allow us to look at what effects (if any) this would have on adult mice.
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1.1 The Lung
Lung Function
The lung is a complex organ composed of more than 40 different cell types whose main
function is in gaseous exchange (7, 8, 9, 10, 11). The various cell types are heterogeneously
distributed within a highly complex framework of branching that eventually terminates with
the alveoli. Gaseous exchange occurs across the thin epithelium of the millions of alveoli
which have a surface area of approx.100m2 which is sufficient to carry out gas exchange for
the entire body, which is important as every single cell in the body needs a constant supply of
oxygen in order to produce enough energy to grow, repair or replace itself and to maintain
vital functions (12). The pulmonary epithelium has a number of functions other than gaseous
exchange. It provides a protective barrier between the host and the outside environment by
segregating inhaled foreign agents, and it also controls the movement of solutes and water,
contributing to the maintenance of lung fluid balance (13). Lung epithelium plays a role in
the metabolism of endogenous mediators and is capable of regeneration, allowing normal cell
turnover and restoration of airway and alveolar functions after lung injury. Lung epithelium
produces surfactant and several proteins which are important as part of the immune defences
of the body (14).
Lung Structure:
The respiratory system (shown in figure 1.1) can be divided into upper and lower. The upper
respiratory system is comprised of the nasal cavity, paranasal sinuses and the nasopharynx.
The lower respiratory tract begins at the larynx followed by the trachea which divides to form
the right and left primary bronchi each of which divides to form secondary (lobar) bronchi
and then tertiary (segmental) bronchi. Tertiary bronchi divide into numerous bronchioles. The
terminal bronchioles divide into the respiratory bronchioles, alveolar ducts and alveolar sacs
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which open into the alveoli. The respiratory epithelium undergoes progressive transition from
tall, pseudostratified columnar, ciliated form in the larynx and trachea to a simple, cuboidal
non-ciliated form in the alveoli .

Figure 1.1: diagram illustrating the overall structure of the respiratory system (15)
It is the alveoli which perform the function of gaseous exchange. The alveolar wall is made
up of epithelial cells, supporting tissues and blood vessels. The epithelial layer consists of
type I and type II pneumocytes. Type I pneumocytes are part of the gaseous diffusion barrier
while the type II pneumocytes secrete surfactant which serves to reduce surface tension in the
alveoli and prevents alveolar collapse during expiration .

Lung Development:
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In mammals most of the structural development and maturation of the lung takes place in
utero (16). In humans, there are four stages of pre-natal lung development (shown in Figure
1.2):
1. Embryonic (up to 7 weeks gestation)
2. Pseudoglandular (5-17 weeks of gestation)
3. Canalicular (16-27 weeks of gestation)
4. Alveolar (27 weeks gestation to term)

Figure 1.2: diagram of lung development showing the time points at which different
structures appear (16).
During the pseudo glandular phase of lung development, major development events occur in
which the airway wall cells differentiate into cartilage, sub mucosal gland, bronchial smooth
muscle and epithelial cell types. The epithelium differentiates into type I and type II
pneumocytes during the canalicular stage.
The blood vessel network develops at the same time as the airways. At 28 days gestation,
groups of endothelial cells can be found in the mesenchyme. At 34 days, capillaries lined by
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endothelial cells surround the two primitive lung buds. As branching of the developing
airways proceeds, each new bud is surrounded by a halo of endothelial cells (16).
Molecular Regulation of Lung Development:
Genetic factors are critical to early lung morphogenesis and post natal maturation. Alteration
of any of the essential genes disturbs the regulation of development and results in neonatal
lung disease and abnormally developed lungs. Abnormally developed lungs have a higher
propensity towards lung disease such as chronic obstructive pulmonary disease (COPD) and
asthma. Growth factors mediate tissue interactions and regulate a variety of cellular functions
that are critical for normal lung development and homeostasis (17). Epidermal growth factor
(EGF) members have been implicated in the development and maturation of the respiratory
system in a diverse range of animal species. It has been found that mice deficient in EGF
receptor (EGFR) show delayed lung maturation which is characterised by poor
alveolarisation and abnormal branching. Decreased alveolarisation and septation in these
mice correlates with low expression of surfactant protein C (SP-C) and thyroid specific
transcription factor (TTF-1) (11). EGF and EGFR are increased in lungs with
BronchoPulmonary Dysplasia (BPD) and fibrosis. Over-expression of the EGFR ligand and
tumour growth factor alpha (TGFα) in perinatal lungs causes disrupted alveolarisation and
vascularisation which leads to fibrosis in adulthood.
Among the essential factors that regulate lung development, EGF signalling is important for
both early stage and late- stage lung development. Ablation of EGFR leads to reduced lung
branching and changed epithelial cells.
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Lung Disease:
Lung disease is classed as any disorder where lung function is impaired (18). Lung disease is
the number three killer (behind heart disease and cancer) in the USA and is responsible for
one in six deaths. Deaths due to heart disease are falling while in contrast, deaths due to lung
disease are increasing each year (19). lung disease can occur as a result of a number of
different factors such as exposure to tobacco smoke (both actively and passively), air
pollutants, occupational exposure to foreign particles such as silica dust or asbestos,
carcinogens, infectious agents and overactive immune system defences (18). In many cases
there is not just one single cause that can be attributed to the lung disease present, often the
disorder is caused by a number of the factors outlined above. Diseases which affect the
respiratory system include: obstructive lung diseases like asthma and emphysema, respiratory
distress syndrome, pulmonary oedema, pulmonary fibrosis and lung cancer. Infectious agents
affecting the lung include respiratory syncytial virus (RSV), TB, influenza as well as other
bacteria and viruses (18). Genetic factors may also affect lung function, a well known
example of this being Cystic Fibrosis.
Irish Lung disease morbidity and mortality
Ireland has the highest death rate from respiratory disease in Western Europe (almost twice
the EU average) with deaths now exceeding those from coronary artery disease. Respiratory
disease kills one in five people in Ireland. The second most commonly reported long-term
illnesses in young adults (under 44 years old) are conditions of the respiratory system. Lung
cancer is the third most common cancer in both men and women. Survival rates for lung
cancer are very low – the one year survival rate is 23.7% and the five year survival rate is
8.6%. Respiratory tuberculosis remains a significant problem although the incidence rate per
100,000 has remained largely unchanged since 2000 (20). Because of the increasing numbers
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of deaths due to lung disease and the numbers of people living with chronic lung disease it
has become increasingly important to study the mechanisms involved in both initial
development and later function of the lung. By looking at what factors control lung function
and development, we may gain clues as to what goes wrong in different conditions causing
lung problems. Only by understanding what has gone wrong can we begin to devise solutions
and potential new treatment options to prolong the life of affected individuals.
By looking at the signalling pathways which become activated following injury or tissue
damage we may be able to come up with intervention strategies to limit any damage caused.
We hypothesised that there may be a re-emergence of the pathways seen in the
developmental stages in response to lung damage.
Lung Cancer
Lung cancer is the fourth most common cancer in Ireland. 20% of all cancer deaths in Ireland
are from lung cancer and with the indidence among Irish women increasing, it is likely to
become an even more prevalent disease (21). In theory, lung cancer is an almost preventable
disease as 85-90% of cases have been attributed to smoking (21, 22)
The two main types of lung cancer are non-small cell lung cancer (NSCLC) (more common)
and small cell lung cancer (SCLC) (15). SCLC is highly aggressive, almost always occurs in
smokers and is rapidly growing. NSCLC is more variable and severity depends on its
histological type (22). The prognosis for patients with lung cancer is primarily dependent on
the stage of the tumour at the time of diagnosis. Patients diagnosed early with stage I tumours
have a 40-70% survival following surgical resection (23).
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Risk factors for developing lung cancer:
Smoking remains the leading risk factor and is associated with 90% of cases in women and
79% in men. Asbestos exposure is the most common occupational risk factor. Other factors
include exposure to radon, arsenic, chromium, nickel. Pre-existing lung diseases such as
tuberculosis, Chronic Obstructive Pulmonary Disease (COPD) and idiopathic pulmonary
fibrosis also increase the risk of developing lung cancer (24).
Around 10% of lung cancers in asymptomatic patients are detected on chest radiographs, but
most patients are symptomatic when diagnosed and can present with the nonspecific systemic
symptoms of fatigue, anorexia, and weight loss (24). Table 1A below shows the treatment of
lung cancer based on its stage.
Treatment of Lung Cancer According to Stage

Stage
Non–small cell carcinoma
I
II

Primary treatment
Resection
Resection

Adjuvant therapy

Chemotherapy
Chemotherapy with
or
without
radiotherapy
IIIA (resectable)
Resection with or without Chemotherapy with
preoperative chemotherapy or
without
radiotherapy
IIIA (unresectable) or IIIB Chemotherapy
with None
(involvement of contralateral concurrent or subsequent
or supraclavicular lymph radiotherapy
nodes)
IIIB (pleural effusion) or IV Chemotherapy or resection None
of primary brain metastasis
and primary T1 tumour
Small cell carcinoma
Limited disease
Chemotherapy
with None
concurrent radiotherapy
Extensive disease
Chemotherapy
None

Table 1A: treatment options for lung cancer by stage (24)

Five-year
survival
rate (%)
60 to 70
40 to 50

15 to 30

10 to 20

10 to 15
(two-year
survival)
15 to 25
<5
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Evidence suggests that the Epidermal Growth Factor Receptor (EGFR) is involved in the
development of various cancers. The EGFR and EGF-like peptides are often over-expressed
in human carcinomas, and in vivo and in vitro studies have shown that these proteins are able
to induce cell transformation. Evidence suggests that cooperation of multiple ErbB receptors
and cognate ligands is necessary to induce cell transformation. In particular, the growth and
the survival of carcinoma cells appear to be sustained by a network of receptors/ligands of the
ErbB family. This phenomenon is also important for therapeutic approaches, since the
response to anti-EGFR agents might depend on the total level of expression of ErbB receptors
and ligands in tumor cells (25)
Our gene of interest, Mig-6, has been shown to be a negatiove regulator of EGF signalling so
we were interested in looking at this pathway and what occurs when Mig-6 is ablated or
knocked out.

1.2 Mouse Models to study disease development and progression
The use of mouse models allows us to manipulate various elements of the mouse genome to
investigate factors involved in disease development and progression in addition to aspects of
the oncogenic process. It also gives the chance to test potential therapeutic interventions. The
success of a mouse model is dependent on its ability to target the specific oncogenic
modification in a cell specific manner. The timing of the genetic modification is also crucial.
Mouse models are most commonly used to investigate the effect of specific gene ablation on
the mouse. Two of those in use are conventional knockout models and conditional knockout
models. Conventional models work on the basis of mutating or ablating endogenous genes by
using homologous recombination in embryonic stem (ES) cells. Specific genes are targeted in
vitro and the ES cells with the target modification are injected into 3.5 day old mouse

18

embryos. The ES cells incorporate themselves into the germline and the mutation is then
transmitted to future generations of mice. The disadvantage of this method is that if the
mutation introduced affects the ability of the mice to survive, the role of the gene in disease
development or in the adult mouse cannot be studied.
Depending on the promoter used to express the transgene, initiation of expression of the
transgene will be at different times. For example expression of genes under the control of the
SP-C promoter is initiated at embryonic day 10 while genes under the control of a CCSP
promoter are initiated at around day 17 of embryonic development. Expression of genes that
disrupt the different developmental stages results in an embryonic lethal phenotype which
makes those models of little value when one is interested in following the progression of a
particular disease or cancer. (7, 8, 9)
Another limitation in using conventional mouse models is that once transcription of the
transgene has been initiated it is irreversible. The ability to terminate transgene expression
would allow identification of the stages of tumour progression independent of the growth
promoting properties of the transgene.
As well as the lethal phenotype mentioned above, conventional models may also result in a
number of non-lethal phenotypes:
-

Artefacts can arise due to the lack of a gene product for the entire lifetime of the
animal

-

Presence of a selection marker can influence the phenotype of the mutation (26)

Conditional transgene models have overcome these limitations.
Conditional knockout models use tissue specific expression of recombinases to ablate genes
in a cell and tissue specific manner. Site specific recombinases splice DNA segments which
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are flanked by specific recognisable sequences. Homologous recombination in ES cells is
used to insert recombinase recognition sequences around a gene of interest or regulatory
exons. This technology is used to express site specific recombinases in a tissue specific
manner. This allows the gene of interest, flanked by recombinase sites, to be deleted in a
tissue specific manner (7, 8, 9, 10).
Site specific recombinases (SSRs) such as Cre and flp are capable of recombining specific
sequences of DNA with high fidelity without the need for co-factors and have been used to
create gene deletions, insertions inversions and exchanges. Both Cre and flp recombine DNA
at defined target sites and are members of the λ integrase superfamily of SSRs (27).
Another commonly used recombinase is the PhiC31 phage integrase (a Streptomyces phage)
(28)
For the purposes of our experiments we were interested in the Cre-loxP system.
Cre-loxP system:
The most common recombinase system in use is the Cre-LoxP system.
The Cre-lox mechanism was first observed in P1 bacteriophage where it is part of the normal
viral life cycle allowing replication of its genomic DNA when reproducing.

Since its

discovery the Cre-lox system has been developed into a technology for genome manipulation
(29). The site specific recombinase Cre of the bacteriophage PI recognises specifically 34bp
long sequences called loxP (locus of X over in PI) (30). Cre excises a segment of DNA
flanked by two loxP sites. Depending on the position and orientation of loxP sites several
outcomes are possible- gene deletions, duplications, inversions and chromosome
translocations. Mostly this system is used to conditionally activate or inactivate certain genes
(31).
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To be successful, Cre-lox requires only two elements to be present:
1. Cre Recombinases: catalyses recombination between two loxP sites
2. loxP sites: 34 base pair sequence containing two 13bp inverted repeats flanking an
8bp core sequence

Figure 1.3: 34 base loxP sequence. The core sequence (shaded) is flanked by two
inverted repeats (29)
This traditional type of Cre-lox system has a number of issues which can make it difficult to
interpret the knockout phenotype (26):
1. If a selective marker is present it may have an influence on the phenotype of the
mutation.
2. As the gene is knocked out for the lifetime of the transgenic animal, artefacts can
develop.
3. Inactivation of some genes can cause lethality in utero which makes it impossible to
look at the gene’s function later in development or post-natally.
A variation of the Cre-lox system has found a way to potentially overcome these limitations.
This version is a conditional gene targeting method based on the inducible activity of an
engineered DNA recombinase. An inducible system allows control over the timing of the
recombination event and also allows tissue specific removal of the target gene (26). In these
inducible forms of Cre, the ligand binding domain of a mutated human oestrogen receptor
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(ERT) (which recognises Tamoxifen and its derivatives but not normal oestrogen) is fused to
Cre (31). This Cre-ERT is a functional Tamoxifen-dependent recombinase in cultured cells
and in transgenic mice (26). By controlling the time point at which the target gene is excised
using an inducible Cre recombinase, it allows us to look at the role of the gene later in the
developmental process or in adult life as well as allowing tissue specific excision of the gene
of interest. Studies have proven the validity of using the Tamoxifen dependent recombinase
by showing excision of the gene in animals where the drug had been administered but no
excision in animals that received no Tamoxifen treatment (26).
1.3 Cell Signalling
Overview of cell signalling:
Cell to cell communication in multicellular organisms is essential in order to ensure
coordination of activities within the organism as a whole (32). Initiation of signal
transduction occurs when a small molecule known as a ligand binds to its receptor protein
often causing a conformational change in this receptor protein. Most signal receptors are
plasma membrane proteins. There are many types of cell membrane receptors (32), three of
which are listed below:
1. G-protein coupled receptors (GPCR)
GPCR contain 7 transmembrane alpha helical domains that bind to extracellular
ligands via their extracellular domain. This in turn leads to a conformational change in
their intracellular domain that results in the activation of G proteins in the cytoplasm
by replacing GDP with GTP. This newly activated protein can then bind to another
protein, which is usually an enzyme, and initiate the next step in the amplification of
the signalling pathway. This activation is relatively short lived because the G protein
contains endogenous GTPase activity that rapidly hydrolyses GTP to form GDP.
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2. Receptor tyrosine kinases
These receptors have enzymatic activity within a cell and will be further discussed
later.
3. Ion channel receptors
Ion-Channel Receptors are channel proteins in a plasma membrane that can open or
close in response to a change in the local concentration of a ligand that binds
specifically to the ion channel receptor. These channels are usually specific for a
single ion (e.g. Ca2+ or Cl-) are important in the functioning of the nervous system
(33).
Receptor Tyrosine Kinases:
Receptor tyrosine kinases (RTKs) mediate cell-to-cell communication and are essential
components of cellular signalling pathways which are active during both embryonic
development and adult homeostasis. Many RTKs have been implicated in the onset or
progression of various cancers, either through receptor gain of function mutations or through
receptor/ligand overexpression (34).
RTKs are receptors which are found in the plasma membrane and are usually activated by
ligand induced oligomerisation which juxtaposes the cytoplasmic tyrosine kinase domains.
This allows autophosphorylation of tyrosine residues which in turn causes a conformational
change which increases kinase activity (as shown in figure 1.4). Some phosphorylated
tyrosine residues can attract various different downstream signalling proteins (enzymes and
adapter proteins), typically through Src-homology-2 (SH2) or phosphotyrosine-binding
(PTB) domains (34, 35).
Signal transduction pathways via receptor tyrosine kinases play pivotal roles in numerous
aspects of physiological and pathological biology. The EGFR family, in particular, has been
extensively studied as a prototype of RTKs since the 1980s (36).
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Epidermal Growth Factor Receptor (EGFR):
EGFR and closely related family members, ErbB2, ErbB3 and ErbB4 are RTKs which send
signals into the cell to regulate many critical processes (37). These receptors are at the apex
of complex signal transduction cascades in a large number of cell types which modulate cell
proliferation, survival, adhesion, migration and differentiation (38, 39).
Structure of EGFR
EGFRs are transmembrane receptors which have an N-terminal extracellular ligand-binding
domain and a C-terminal cytoplasmic region which has enzymatic activity. This structure
allows signals to be transmitted across the plasma membrane (39).

Figure 1.4: The above diagram shows a general view of the ligand-induced dimerization
and activation process of EGFR (40)
Signalling via EGFR:
Signalling through the receptor begins when a ligand (EGF, EGF-like molecules, TGF-α and
neuregulins) binds to the extracellular domain causing a conformational change and the
signal is transmitted to the intracellular kinase domain. The kinase domain phosphorylates
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several tyrosine residues in the C-terminal tail of the receptor which recruits PTB and SH2
domains containing signalling proteins and relays the signal to downstream signalling
pathways (37)

Figure 1.5: The epidermal growth factor receptor (EGFR) signal transduction model.
Ligand binding to receptors on the cell surface induces receptor dimerisation and cross
phosphorylation. A transient signalling complex composed of effector and adaptor proteins is
then assembled. Dissociation of this complex leads to an enzymatic cascade culminating in
gene activation and a cellular response. During signal termination, ligand–receptor complexes
are internalised through clatherin-coated regions of the plasma membrane and then either
degraded or recycled to the cell surface (39).
EGF signalling is important in early and late stage lung development and its ablation leads to
reduced lung branching and alterations in epithelial cell population (41). EGF can also
activate downstream signalling, Ras-PI3K/Akt and Ras/MAPK and cross-talk with other
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growth factors such as TGF-β1 and HGF signalling which are all important in lung
development (5).

Feedback inhibition of EGFR signalling:
Signalling networks need to be coordinated in a strictly controlled manner and negative
regulators have been shown to have an important role in this regulation. Continuing research
has shown that a number of negative regulators exist which play major roles in regulating
signalling networks via multiple modes of action. The coordinated action of positive and
negative regulators provides the fine tuning necessary to maintain correct signalling pathways
(42). It has been seen that loss or decrease in expression of negative regulators can be linked
to cancer development (36).
Negative regulators of EGFR signalling include the following:
-

Mitogen inducible gene 6 (Mig-6)/RALT/Gene 33 (43)
o This is an early-response gene induced by EGF. Its transcription is induced by
the extracellular signal-regulated kinase (ERK) pathway that is activated by
growth factors such as EGF or by multiple stimuli, including osmotic and
mechanical stress. Mig-6/RALT/Gene 33 binds to the tyrosine kinase (TK)
domains of EGFR and ErbB2 and inhibits TK activity.
o Studies of the crystal structures that form between Mig-6 and the kinase
domain of EGFR have shown that an approximately 25 residue epitope of
Mig-6, known as segment one, binds to the distal surface of the C lobe of the
kinase domain. Other analyses (biochemical and cell based studies) confirm
that this interaction, seen on examination of the crystal structures, contributes

26

to EGFR inhibition by blocking the formation of the activating dimer
interface. (44, 45)

-

Fibroblast growth factor receptor substrate 2 beta (FRS2β)
o FRS2β constitutively binds to EGFR, regardless of ligand stimulation. After
activation of ERK by various growth factors, including EGF, the
phosphorylated ERK binds to FRS2β and inhibits EGFR autophosphorylation
and signal transduction. Thus, FRS2β acts as a negative feedback regulator of
EGFR (46).

-

Suppressor of cytokine signalling 3 (SOCS3)/SOCS4/SOCS5
o Is an early-response gene induced by EGF. SOCS proteins are negative
feedback regulators of EGFR. They bind to autophosphorylated EGFR via
their SH2 domains and recruit E3 ubiquitin ligase complex via their SOCS
domains, leading to the ubiquitinylation and degradation of EGFR(47).

-

Leucine-rich repeats and immunoglobulin-like domains 1(LRIG1)
o

An early-response gene induced by EGF. LRIG1 acts as a negative feedback
regulator of EGFR (48). It binds to EGFR via its extracellular domain and
recruits Cbl – an E3 ubiquitin ligase – via its cytoplasmic domain, leading to
the ubiquitinylation and degradation of EGFR (36).

The modes of action of these inhibitors are shown in figure 1.6 below
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Figure 1.6: Multiple modes of action of the inhibitors. (A) Mig-6/RALT transcription is
induced by the activation of ERK pathway via activated EGFRor other stimuli. The translated Mig6/RALT binds to the activated TK domain of EGFR and ErbB2 and inhibits the TK activity. (B)
FRS2β constitutively binds to EGFR. Activated EGFR or other stimuli activate the ERK pathway.
The activated ERK binds to FRS2β and inhibits the EGFR signalling. (C) SOCS3, SOCS4, or SOCS5
transcription is induced by stimulation with EGF. The translated SOCS3/SOCS4/SOCS5 binds to the
autophosphorylated EGFR via its SH2 domain and recruits the E3 ubiquitin ligase complex via its
SOCS box. (D) LRIG1 transcription is induced by stimulation with EGF. The translated LRIG1 binds
to EGFR family members via its extracellular domain and recruits Cbl E3 ubiquitin ligase to its
cytoplasmic tail, inducing ubiquitinylation/degradation of the EGFR family members (36)

HGF signalling:
Hepatocyte growth factor/scatter factor (HGF) is a multifunctional factor produced by many
cell types, including normal fibroblasts, epithelial and endothelial cells, but also different
oncogenic cells.
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Mesenchymal-epithelial tissue interactions are important for development of various organs,
and in many cases, soluble signalling molecules may be involved in this interaction.
Hepatocyte growth factor (HGF) is a mesenchyme-derived factor which has mitogenic,
motogenic and morphogenic activities on various types of epithelial cells and is considered to
be a possible mediator of epithelial-mesenchymal interaction during organogenesis and organ
regeneration. It has been suggested that HGF is a putative candidate for a mesenchymederived morphogen regulating lung organogenesis (49).

HGF has been reported to influence cell proliferation of hepatocytes and multiple other cell
types, kidney cell migration, organ and tissue development, but also the invasiveness of
tumour cells and other biological responses (50, 51). HGF binds to the receptor tyrosine
kinase c-Met which transmits the HGF signal into the cytoplasm (52). c-Met
autophosphorylation leads to the recruitment of signal transduction proteins like the c-Src
kinase, phospholipase C-g, the Grb2zSoS complex, and phosphatidylinositol 3-kinase (51).

The mature HGF protein binds to its high-affinity receptor c-MET, leading to its activation
and phosphorylation of multiple serine and tyrosine residue sites. The extracellular Sema
domain of c-MET mediates binding to the ligand HGF, which, subsequently, leads to receptor
dimerisation and activation of its intrinsic tyrosine kinase. The c-MET/HGF pathway has
gained considerable interest through its apparent deregulation by overexpression or gain-offunction mutations in c-MET in various cancers, including lung cancer (53, 54). The figure
below (1.7) illustrates the interaction of HGF and c-MET and the resulting pathways which
are stimulated (54).
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Figure 1.7: shows the versatile signalling functions of c-MET/HGF pathway regulating
various biological functions of the cells, including cytoskeletal functions, cell proliferation
and differentiation, survival, and apoptosis. Various potential serine, threonine and tyrosine
phosphorylation sites on the signalling phosphoprotein intermediates are included (54).
The ability of HGF to stimulate mitogenesis, cell motility and matrix invasion means it has a
central role in angiogenesis, tumourogenesis and tissue regeneration (51). There is evidence
that HGF plays an essential part in parenchymal repair and protection in various organs. In
the lungs, HGF is a potent regenerative and cytoprotective factor during organogenesis or in
cases of acute injuries (55). c-MET is normally expressed by epithelial cells but is also found
on endothelial cells, neurons, hepatocytes, haematopoietic cells and melanocytes. HGF
expression is restricted to cells of mesenchymal origin (49, 56).
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1.4 Mig-6
Mig-6 is an immediate early response gene (& adapter protein) that is transcriptionally
induced by a divergent array of extracellular stimuli including various growth factors,
cytokines and stress factors as well as by the Ras oncoprotein (1, 2, 3). Mig-6 is also known
as receptor associated late transducer (RALT), gene 33 (in rat) and ERBB feedback inhibitor
1 (ERFFI1) (2). Mig-6 has been mapped to human chromosome 1p36 and to the distal region
of mouse chromosome 4 (4). The Mig-6 gene spans ~13.8kb and contains four exons
including the non-coding exon 1 and the coding exons 2-4. The Mig-6 full length transcript is
3.1kb and encodes a protein of 461 amino acids (6).
At least five functional regions have been identified in the Mig-6 gene which are:
1. Threonine/serine phosphorylation region
2. Src-homology 3 (SH3) binding domain
3. Cdc42/Rac interaction and binding (CRIB) domain
4. 14-3-3 binding domain
5. ErbB-2 binding domain (5)
The Mig-6 gene has a number of features including the following: it is present only in higher
animals such as humans and rodents but not in lower ones like Drosophila or C.elegans. This
suggests that Mig-6 was acquired during evolution for regulating more complex signalling
networks. Secondly, since it is an immediate early response gene its expression can be rapidly
induced, it may play an important role in early regulation of cellular responses (4).
Transcriptional regulation of Mig-6:
Mig-6 expression can be induced by a wide variety of external stimuli, a summary of some of
which are listed in table 1B below
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Transcriptional inducers of Mig-6 expression
Growth Factors

Stresses

Hormones/Others

EGF

Diabetic nephropathy

Glucocorticoids

FGF

Hypoxia

Insulin

HGF

Live Staphylococcus infection

Retinoic acid

TGF-α

Ventilator induced lung injury

Alklyating agents

PDGF

Mechanical strain

cAMP

Table 1B: Summary of the transcriptional inducers of Mig-6 expression (4)
Various inducers can differentially activate the regulation of Mig-6 and may use different
intracellular pathways to accomplish this regulation. The induction of Mig-6 by growth
factors such as EGF is mediated via the Ras-MEK-ERK pathway. The MEK-ERK pathway is
also responsible for Mig-6 induction by serum, phorbol and sorbitol induced osmotic stress.
Regulation of insulin induced Mig-6 expression varies in different cell types. The PI-3K and
ERK pathways are involved in hypoxia induced Mig-6 expression (4).
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Figure 1.8 shows the known and potential actions of Mig-6 on the EGF, HGF/SF and certain
stress induced signal transduction.
Mig-6 in development, homeostasis and stress response:
Mig-6 expression levels differ among different tissues and also in the same tissues at different
time points during foetal development and adult maturation. The mouse liver contains high
levels of Mig-6 while varied levels are present in the lung, placenta, heart, brain, stomach and
skeletal muscle. The foetal liver shows low levels of Mig-6 expression while a sharp increase
is observed in the newborn liver (this suggests that, at birth, the hepatocytes respond to
hormonal and/or environmental changes) (4). The level of Mig-6 expression in the lung
differs throughout the gestational period as can be seen in Figure 1.9 below:
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Figure 1.9: Differential expression of Mig-6 during murine lung development. (A) Mig-6
relative mRNA levels in E13.5, E14.5, E15.5, E16.5, E17.5, E18.5, P1, P3, P4, P5, P10, and
adult (3-month-old, AD) lungs by quantitative real-time RT-PCR. (5)
E13.5→E18.5: embryonic day 13.5-day 18.5. P1→P10: pups day 1→10.
In mice, genomic disruption of the mig-6 gene leads to degenerative joint diseases, skin
cancer, lung cancer and gastrointestinal tract tumours. It has been demonstrated that ablation
of Mig-6 results in a partial lethal phenotype with 50% of these mice dying during the
neonatal period (5).
Mig-6 is a negative regulator of EGF signalling
Mig-6 can be transcriptionally induced by EGF, and it acts as a negative feedback inhibitor of
EGF receptor signalling by blocking formation of the activating dimer interface (44). Mig-6
interacts with the EGFR in vivo in an EGF-inducible manner (58). Overexpression of Mig-6
in vitro leads to inhibition of ErbB2 autophosphorylation and reduced MAPK pathway
activity, through binding of Mig-6 to ErbB receptors (2).
The C-terminal region of Mig-6 contains a segment (residues 323-372) which is essential for
EGFR and ErbB2 binding. Studies of the crystal structure of the area around this segment has
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defined a 25-residue epitope of Mig-6 that binds to the EGFR (ErbB2) kinase domain and has
been given the term segment 1. The footprint of Mig-6 (segment 1) on the kinase domain of
EGFR overlaps the cyclin-like face of the kinase domain in the asymmetric kinase domain
dimer, and so binding of Mig-6 to an EGFR kinase domain will prevent it from acting as a
cyclin-like activator for other kinase domains. Residues in the Mig-6 binding interface of
EGFR are conserved suggesting that Mig-6 could potentially bind to other members of the
EGFR family. Introduction of individual mutations in Mig-6 (segment 1) interrupts the
binding of EGFR and Mig-6, proving that it is segment 1 which is important for inhibition of
EGFR. An interesting property of Mig-6 is its ability to bind more tightly to activated EGFR
than to the unbound receptor (44).
Mig-6 as a tumour suppressor gene
Mig-6 localises in human chromosome 1p36, a locus that has been widely suggested to
harbour putative tumour suppressor genes including EXTL1 (a candidate neuroblastoma
suppressor gene) as well as p73, the p53 tumour suppressor gene homolog. No mutations in
p73 have been identified in human lung cancer so it can be discarded the responsible tumour
suppressor in the lung. Allelic imbalance of chromosome 1p36 is one of the most frequent
genetic alterations observed in various human cancers (3).
It is plausible to consider Mig-6 as a potential tumour suppressor gene for many different
reasons, some of which are listed below:
-

It is located on chromosome 1p36.12-36.33, a locus considered a hot spot of allelic
imbalance for lung cancer (3)

-

Loss of function mutations in Mig-6 have been identified in human lung cancer cell
lines
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-

It is negative regulator of receptor tyrosine kinase signalling from EGF and HGF,
whose receptors have been shown to play important roles in lung malignancy (3)

Mig-6 knock-out models have been developed in order to further study the role of Mig-6 in
different organs both during foetal development and after birth into adulthood. One such
model has been generated in the DeMayo laboratory at Baylor College of Medicine. The
embryo lethal phenotype and multi-tissue carcinogenesis of the Mig-6 null allele make it
difficult to investigate the impact of ablation of Mig-6 on specific tissue and at specific time
points in development. In order to look at the role of Mig-6 in specific tissues, a conditional
knock out model would be useful. The DeMayo lab have successfully generated a conditional
null allele, Mig-6f/f, by introducing LoxP sites that flank exons 2 and 4 of the Mig-6 gene.
The Mig-6 conditional null allele was validated in the recombined Mig-6-/- mice by
measuring Mig-6 mRNA and protein in the liver, lung, uterus and skin. Neither mRNA nor
protein of Mig-6 could be detected by real time RT-PCR or Western blot analysis in the liver,
lung, uterus and skin of recombined Mig-6-/- mice (34).The recombined Mig-6-/- mice
developed pathological changes such as degenerative joint diseases and skin hyperplasia,
similar to the previously reported Mig-6 germline null allele. These mice also had enlarged
uteri with endometrial hyperplasia. This Mig-6f/f mouse is used as a valuable tool in the study
of Mig-6 in a tissue specific manner (6).

36

Aims:
We approached our work with two main aims which were to use animal studies and cell
studies to look at the role of Mig-6.
In our animal studies we planned to use the previously mentioned conditional knockout
model to look at what occurs in murine lungs when Mig-6 is ablated. We would analyse our
results using quantitative real time pcr and Western blot analysis.
The cell studies would focus on epithelial and endothelial cells. We aimed to knockdown
Mig-6 expression in these cells using siRNA to determine what effects (if any) this would
have on cellular survival and also what pathways may be involved in response. We would
also look at EGF stimulation studies in both cell types. Again we would look at our results
using real time pcr and Western blot analysis.
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2. Materials and Methods
Animal strains used:
We used the Mig-6f/f mice in order to study the role of Mig-6 in adult mice by developing an
inducible ablation model which produced our Mig-6d/d mice. To obtain our Mig-6d/d mice,
Rosa26-Cre-ERT2 mice were crossed with Mig-6flox/flox mice and the resulting Rosa26-CreERT2; Mig-6flox/flox (Mig-6d/d) or Mig-6flox/flox (Mig-6f/f) mice (2 months old) were
injected peritoneally with 1 mg of Tamoxifen for 5 days. These mice were further maintained
for 4 months before analysis. It was expected that in the Mig-6d/d mice Mig-6 would have
been successfully ablated. At six months old mice were sacrificed, lung tissue harvested and
our experiments carried out.

2.1: siRNA treatment of epithelial and endothelial cells
Materials
-

siRNA (Thermo Scientific, Dharmacon)- ON-TARGET plus SMART pool human
Mig-6

-

Penicillin/Streptomycin (100X) (GIBCO)

-

Lipofectamine 2000 reagent (Invitrogen)

-

Opti-MEM (Invitrogen)

-

Culture Plates (Grenier labortechnik)

-

RPMI 1640 (Invitrogen)

-

FBS (Invitrogen)
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2.1 siRNA treatment of epithelial and endothelial cells
siRNA treatment was carried out on these epithelial and endothelial cells in order to knock
down Mig-6 and investigate the effect (if any) this would have on genes downstream from
Mig-6 in signalling pathways. We were also interested to see whether knocking down Mig-6
would affect cell viability. Protein and RNA were isolated from the treated cells for Western
blot and real time PCR analysis.
The H441 human bronchiolar epithelial cells (National Cancer Institute, Frederick, MD) were
grown in RPMI 1640 (+ 10% FBS + P/S (penicillin/streptomycin)) until 40% confluency.
Human lung micro vascular endothelial cells (HMVEC-L, Lonza, Walkersville, MD) were
maintained in Endothelial Cell Medium containing hEGF, hydrocortisone, GA-1000, FBS,
VEGF, hFGF-B, R3-IGF-1, and ascorbic acid (Bullet Kit, Lonza) until 60% confluency.
Cells were cultured in the Tissue Culture Core (TCC) at Baylor College of Medicine. Culture
medium was RPMI 1640 medium supplemented with 2 mM L-glutamine, 1.5 g/l sodium
bicarbonate, 4.5 g/l glucose, 10mM HEPES (pH 7.4), 10% foetal bovine serum, and 1%v/v
antibiotics to prevent bacterial growth. Cells were cultured at 37oC in 5% CO2 and passaged
every 3 days.
Cells were transfected with 50 nM of control siRNA or SMART pool of human Mig-6
siRNA (Dharmacon, Chicago, IL) in serum-free OptiMEM (Invitrogen, Carlsbad, CA).
For each 6 well culture plate the following steps are carried out.
33µl of lipofectamine with 660µl of opti-MEM is mixed (by pipetting ~50 times) and left to
settle for 30mins. To each of six microtubes 100µl of opti-MEM was added along with the
volume of siRNA required to give a final concentration of 50nM. 100µl of opti-MEM
containing lipofectamine was added to the opti-MEM containing siRNA mixed by pipetting
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approx. 50 times and left to settle again for 30 min. A tube containing opti-MEM, 2% FBS,
and 1%v/v antibiotics was prepared.800µl of opti-MEM containing 1x antibiotics plus 2%
FBS was added to the lipofectamine siRNA mixture. 1000µl of opti-MEM with 2% FBS,
lipofectamine and siRNA mixture was added to each well. After overnight culture, 1 ml of
RPMI 1640 medium containing 20% FBS and 1% antibiotics was to each well and culture
continued for a further 48hrs. Following culture, protein and RNA were isolated from the
cells for Western blot and real time PCR analysis.
2.2 EGF/HGF induction of Mig-6 in siRNA treated cells
Materials
- 40ng/ml EGF
- 40ng/ml HGF
- BEBM (bronchial epithelial cell basal medium) (Lonza)
- Protein Lysis Buffer (10 mM Tris HCl, pH 7.5, 5 mM EDTA, 50 mM NaCl, 0.1% NP40, 1
mM PMSF, 10 µg/ml aprotonin, and 10 µg/ml leupeptin)- Sterile PBS pH7.4- Cell Star
macroplate with lid (Grenier labortechnik)
- opti-MEM (GIBCO)
2.2 EGF/HGF induction of Mig-6 in siRNA treated cells
NHBE (normal human bronchial epithelial) cells were cultured (in BEBM) and subjected to
siRNA treatment to knock down Mig-6 as detailed for the H441 and HMVEC cells in section
2.1. The siRNA treated cells in culture at ~50% confluency were then subjected to treatment
with 40ng/ml of EGF (epidermal growth factor) and HGF (hepatocyte growth factor) (24hrs
post siRNA treatment) to investigate what effect, if any, addition of these substances would
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have on Mig-6 and other protein levels. siRNA silences Mig-6 expression but it was
hypothesised that addition of either EGF or HGF could induce expression of Mig-6 once
again and levels would increase post administration of the growth factors.
Stock solutions of EGF (100μg/ml) and HGF (10μg/ml) were firstly diluted to a
concentration of 40ng/ml in opti-MEM medium. After siRNA treatment was complete
(72hrs), the media was removed from each culture well, rinsed with opti-MEM and 1ml of
either EGF 40ng/ml or HGF 40 ng/ml was added. Culture plates were incubated at 37oC with
5% CO2 for 0mins, 15mins, 30mins, 1 hr, 2hrs and 4hrs. At each of the above time points the
treated cells were harvested for protein.
2.3 SDS PAGE and Western blot
Materials:
‐

Protein marker- Precision Plus Protein Standards (BIO-RAD)

‐

Gel:
o BIO-RAD ready gel, precast gel for electrophoresis (BIO-RAD)

‐

Mini-Trans Blot Electrophoretic Transfer Cell (BIO-RAD)Gel transfer cell, gel holder
cassettes, fibre pads, electrodes, tank, cooling unit, lid with cables

‐

Milk- Nestle Carnation instant non fat dry milk powder

‐

Weighing scales TR 603D, (Denver Instrument Company)

‐

X-Ray film- HyBlot Cl Premium autoradiography film (Denville Scientific Inc.)

‐

Autoradiography Cassette (Fisher Scientific)

‐

RestoreTM Western blot Stripping Buffer (Thermo Scientific)

‐

AmershamTM ECL Plus Western blotting detection system (GE Healthcare)

‐

PVDF Membrane (0.45µm), Immobilon-P transfer membrane (Millipore)
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‐

Gel Filter Paper (Whatman)

‐

PBS:
o 1LH2O
o 8g NaCl (Sigma)
o 80ml Phosphate buffer pH 7.4 (Sigma)

‐

PBST (Wash Buffer)
o 1L PBS
o 20µl 20%Tween 20 (Fisher Scientific)

‐

Blocking Buffer:
o 100ml PBST
o 1g non-fat dry milk (Nestle)

‐

10x TBS
o 200ml 1M Tris-HCl (pH 7.5)
o 300ml 5M NaCl
o 500ml H2O

‐

Alternative wash buffer (TBST)
o 1x TBS with 0.1% Tween-20

‐

Alternative blocking buffer
o 100ml 1x TBST
o 5g non-fat dry milk (Nestle)
‐

5X running buffer:
o 15.1g Tris
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o 94g glycine
o 50ml 10% SDS
o Make up to 1000ml with water
‐

1x transfer buffer:
o 2.9g glycine
o 2.8g Tris
o 200ml methanol
o Adjust to 1000ml with water

Primary antibodies:
‐

Anti- Met, rabbit polyclonal (Santa Cruz Biotechnology)

‐

Anti-EGFR, rabbit polyclonal (Santa Cruz Biotechnology)

‐

Anti- Akt, Mouse monoclonal (Santa Cruz Biotechnology)

‐

Anti- p-Akt (Ser 473), rabbit polyclonal (Santa Cruz Biotechnology)

‐

Anti-RALT/MIG-6 (PE-16), rabbit polyclonal (Sigma Aldrich)

‐

Anti- Actin, mouse monoclonal ( clone AC-40) (Sigma Aldrich)

Secondary antibodies:

-

‐

Peroxidase labelled rabbit anti-mouse IgG (Santa Cruz Biotechnology)

‐

Peroxidase labelled goat anti-rabbit IgG (Santa Cruz Biotechnology)

Protein lysis buffer
o (10 mM Tris HCl, pH 7.5, 5 mM EDTA, 50 mM NaCl, 0.1% NP40, 1 mM
PMSF, 10 µg/ml aprotonin, and 10 µg/ml leupeptin)

-

Eppendorf tubes

-

Heating block (Fisher Scientific)
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-

Parafilm

2.3 SDS PAGE and Western blot
Protein Isolation from siRNA treated cells:
To harvest the proteins the following was carried out: media was removed from the
appropriate well and 100μl of protein lysis buffer added. A pipette tip was used to scrape the
bottom of the culture well to remove all cells and ensure complete homogenisation. The cell
lysates were transferred to labelled eppendorf tubes, covered with parafilm and boiled for 5
mins to inactivate endogenous enzyme activity such as phosphatase activity.
In the case of our time course studies 100μl of PBS (pH7.4) was added to the resulting empty
culture well and the remaining cells in the culture plate placed back in the 37oC incubator
until the next time point for protein harvesting. In all cases the amount of protein harvested
was measured to allow us to adjust our loading to ensure equal protein amounts were loaded
onto the gel. The lysates could be immediately used for Western blot analysis or frozen at 20oC for future analysis.
Western blot was used to analyse the protein samples collected from H441 epithelial cells,
HMVEC cells and NHBE cells. We wanted to look at the effect knocking down Mig-6 had
on Akt, p-Akt, mTor, p-mTor, c-Met, EGFR and p-EGFR levels in our cells..
The running apparatus was prepared and the gel inserted into the cassette and the comb
removed. The cassette was placed into the tank and 1x running buffer poured in until all wells
were fully submerged. 5µl of protein marker was added to well number one. 20µl of sample
was added to the remaining wells. The apparatus was connected to a power supply and run at
a constant voltage of 100V for approximately two hours. Once the dye front had run approx.
2/3 of the length of the gel the protein was transferred to a PVDF membrane as follows: one
edge of the membrane was labelled and the entire membrane was then submerged in
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methanol. The transfer apparatus was assembled (Black side of cassette down, sponge, filter
paper, gel, membrane, filter paper, sponge), ensuring there were no air bubbles between
layers to hinder an efficient transfer. Once assembled, the transfer apparatus was placed into
the tank. An ice pack was placed in the tank and transfer buffer poured in until the cassette
containing the gel and PVDF membrane was completely covered. This was run at 50-60V for
two hours.
Blocking Step:
Following the transfer step, the membrane was rinsed briefly with PBS. This was followed by
blocking in blocking/staining solution for one hour at room temperature on a plate rocker.
Primary antibody:
Antibodies were diluted as required- 1:1000 in blocking/staining solution. Following the
blocking step, the diluted primary antibodies were applied to the membrane (10ml per
membrane). Primary antibody was incubated at 4oC overnight on a plate rocker.
Washing step:
The following day the membrane was washed with PBST for ten minutes at room
temperature on a plate rocker. This wash solution was discarded and the wash step was
repeated twice to ensure sufficient washing was achieved.
Secondary Antibody
Following the wash step, enzyme-conjugated secondary antibody raised against the primary
antibody was applied (at a dilution of 1:1000). Secondary antibody incubation was for one
hour at room temperature on the plate rocker. Following secondary antibody incubation, the
membrane was washed again as detailed above.
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ECL treatment:
In order to be able to visualise the protein bands, lumigen must be applied to the membrane.
For each membrane ~1ml of lumigen is required. 1ml of lumigen A (GE Healthcare ECL
Plus Western blotting detection system) was mixed with 25µl of lumigen B. The lumigen
mixture was applied to the membrane and incubated for two to three minutes. The membrane
was then transferred to an autoradiography cassette.
In the dark room an autoradiograph film was placed on top of the membranes. Initial
exposure time was ten mins and then reduced or increased depending on the result seen upon
development of the first film. Films were developed by placing the exposed film into the
processor and protein banding patterns were observed. Digital copies of the negatives were
taken using a Sony 10 mega pixel camera and a white light box to back-illuminate the film.
Stripping the membrane for re-use:
In order to re-use the membrane and apply a new set of antibodies all primary and secondary
antibodies bound to antigen on the membrane needed to be first stripped from the membrane.
To do this we used a commercial stripping buffer (containing beta-mercaptoethanol) which
strips off the primary and secondary antibodies while leaving the protein sample on the
PVDF membrane. Approximately 5ml of stripping buffer was applied to the membrane and
incubated for 15mins on the plate rocker at room temperature. Following stripping, the
membrane was rinsed with PBS and blocked with 1% milk for 1 hour at room temperature
followed by the new primary antibody for one hour at room temperature. From this point on
the procedure was followed exactly as detailed above.
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Western blot- alternative procedure:
We began having difficulties with some of our Western blot results so we decided to optimize
the method to enable us to get better, more reproducible results. These changes will be
detailed here and referred to in the relevant results section:
Changes were made to the buffers and blocking solution used. Instead of using PBST we
switched to TBST (Tris buffered saline & 0.1% Tween) for our washing steps and also for
making our blocking solution. Instead of blocking with 1% milk in PBST for one hour we
instead just briefly rinsed the membrane with 5% milk in TBST. Antibodies were diluted in
5% dry milk powder (w/v) in TBST instead of 1% dry milk powder (w/v) in PBST. For each
wash step we reduced the length of time from ten minutes to eight.
2.4 RNA Isolation
Materials:
‐

TRIzol® reagent (Invitrogen)

‐

Chloroform (Fisher Scientific)

‐

Isopropanol (Fisher Scientific)

‐

70% ethanol (PHARMACO-AAPER)

‐

Microcentrifuge tubes

‐

Pipettes -P1000, P200, P20 (Gilson)

‐

Centrifuge

‐

UV spectrometer

‐

TipOne pipette tips (USA scientific Inc.)

‐

DEPC treated water
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2.4 RNA Isolation
RNA was isolated from siRNA treated cells and also from frozen mouse lung tissues. The
RNA was used for real time PCR analysis.
Prior to RNA Isolation from samples, the bench area, pipettes, other instruments and gloves
were sprayed with 70% ethanol to avoid RNase contamination and maximise the amount of
RNA isolated from the samples. All dilutions were made using DEPC treated water.
Cultured cells were lysed directly in the culture dish by adding 1ml of TRIzol® reagent to a
3.5cm diameter dish, and the cell lysate was passed through a pipette several times. The
homogenised samples were incubated at room temperature for five minutes to allow complete
dissociation of nucleoprotein complexes. 0.2ml of chloroform (Fisher Scientific) was added,
sample tubes capped securely and tubes shaken vigorously (by hand) for ~15 seconds.
Samples were incubated at room temperature for two to three minutes and then centrifuged at
12,000 x g for 15 minutes at 4oC. Following centrifugation the sample separated into a lower
red phenol–chloroform phase, an interphase and a colourless upper aqueous phase
(containing the RNA). The aqueous phase was transferred to a fresh tube and RNA
precipitated by addition of 0.5ml isopropyl alcohol (Fisher Scientific). Samples were
incubated at room temperature for ten minutes to precipitate RNA and then centrifuged at
12,000x g for ten minutes at 4oC. After centrifugation the RNA forms a gel-like pellet on the
side and bottom of the tube. The supernatant was removed and the RNA pellet washed with
1ml 70% Ethanol (PHARMCO-AAPER). Sample was mixed by vortexing (Fisher
Scientific) and then centrifuged at 7,500 x g for five minutes at 4oC. After ethanol wash, the
pellet

was

briefly

dried

by

vacuum.

RNA

was

dissolved

in

30µl

DEPC

(Diethylpyrocarbonate) water. RNA was then quantified by UV spectrometry. An aliquot of
each sample was diluted 1 in 65 with a final volume of 260µl (4µl RNA in 260µl water)
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RNA was isolated from frozen lung tissue in essentially the same manner as for cells, with
the following exception. When isolating RNA from the tissue samples, after addition of
TRIzol® reagent (per lung) the tissues were homogenised and placed on ice until all samples
had been homogenised. From this point, the procedure was the same as for the cultured cells.
2.5 Quantitative Real Time PCR
Materials:
‐

5x first strand buffer (Invitrogen)

‐

0.1M DTT (Invitrogen)

‐

Ribonuclease inhibitor, Cloned (Invitrogen)

‐

Hexamer (random primer) (Invitrogen)

‐

MMLV- reverse transcriptase (Invitrogen)

‐

10mM dNTPs

‐

PCR tubes (Fisher Scientific)

‐

iTaq SYBR® Green (BIO-RAD)

‐

96 well optical reaction plate with barcode (ABI PRISM, Applied Biosystems)

‐

MicroAmp™ Optical adhesive film (Applied Biosystems)

2.5 Quantitative Real Time PCR
Quantitative real time PCR was employed to investigate if a successful knock down of Mig-6
had been achieved in our epithelial and endothelial cells and to quantitate expression of a
number of molecular markers in mouse lung tissue.
2.5.i: Reverse Transcriptase PCR (RT-PCR)
Firstly the following was mixed in a tube: 2µg RNA sample, 1µl dNTP, 1µl random primer,
water to a volume of 12µl. This mixture was heated to 65oC for five minutes and then quick
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chilled on ice. The following mixture was prepared and added to the RNA/dNTP/random
primer mix: 4µl 5x first strand buffer, 2µl DTT, 0.5µl RNase inhibitor, 1µl MMLV reverse
transcriptase, 0.5µl water. The RT-PCR mix was put on a thermocycler (MJ Research) and
the following conditions programmed: 25oC 10 mins, 37oC 50 mins, 70oC 15 mins.
This cDNA was stored at -20oC until its use as the template for quantitative real time PCR.
2.5.ii: Quantitative Real-time PCR
Quantitative real-time PCR was performed by using Taqman probe or SYBR Green master
mix (Applied Biosystems, Foster City, CA) to quantitate the expression levels of Mig-6,
surfactant associated protein C (SP-C), T1 , and mucin 5 subtypes A and C (MUC5AC), in
the Mig-6+/+, Mig-6-/-, Mig-6f/f and Mig-6d/d mouse lungs. Primers and probe sequences are
listed in Table 2.1.
cDNA samples were diluted 1 in 5 in DEPC water for Mig-6, SP-C, T1 α and MUC5AC and
a further 1 in 500 for the 18S samples (This follows a protocol already in use in our lab).
Once samples were diluted appropriately the following mixtures were prepared for each
marker being investigated: cDNA 5μl, master mix (containing taq, forward and reverse
primers, MgCl2 and dNTPS) 1μl, H2O 6.5μl. Reactions were prepared in 96 well optical
reaction plates (Applied Biosystems) and the plates sealed with adhesive film to prevent
evaporation during the reaction. Thermal conditions for the reaction were as follows: 50oC
2mins followed by 40 cycles of 95oC for 15seconds and 60oC for 1 minute. Data was
collected at each 60oC point in the reaction. Levels for each target marker were compared for
samples from Mig-6+/+, Mig-6-/-, Mig-6f/f and Mig-6d/d mice.
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Table 2.1: Primer sequences for real-time PCRa
SP-C

Forward: 5'-ACGACGACCACGAATTCCTG-3'
Reverse: 5'-CCTCCCAACTACATGGTGGTG-3'

T1

Forward: 5'-TCAAAGCATCTGCCTTTGGAA-3'
Reverse: 5'-ACTGTCTTGGCTTTGCTCCATT-3'

MUC-5ACb

Forward: 5'- AGAATATCTTTCAGGACCCCTGCT -3'
Reverse: 5'- ACACCAGTGCTGAGCATACTTTT -3'
Probe: 5'- CTCAGCGTGGAGAATG -3'

a

Taqman primers and probes from Applied Biosystem (Foster City, CA) were used for

quantification of gene Mig-6, CC10, and 18S rRNA and the sequences are not listed as they
are not available
b

Primers and probe of MUC-5AC were kindly provided by Dr. Christopher M. Evans from

University of Texas, M.D. Anderson Cancer Centre.
2.6: Measurement of Alveolar Spaces:
Materials
- Images of H&E stained tissues taken at 40x magnification
- Grid
- Ruler
The size of alveolar spaces were measured on sections taken from wild type, Mig-6 knock
out, f/f and d/d mice in order to assess whether any difference in size is seen in the different
mice. It has previously been seen in our lab that Mig-6 knockout mice have larger alveolar
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spaces than wild type mice so we wanted to see if the same was true in our induced knockout
mice.
Measurements were performed on wild type, Mig-6 knock out, f/f and d/d mice. The size of
the alveolar airspace was determined by measuring mean chord lengths on H&E-stained lung
sections (59). Images were taken at 40x from five representative, non-overlapping fields of
lung from at least 8 mice. A grid consisting of 6 black lines at 35-μm intervals (scale) was
overlaid on the image. Areas of bronchiolar airways and blood vessels were eliminated from
the analysis. The length of lines overlapping the alveoli was measured and averaged giving
the mean chord length of the alveolar space. All quantitative studies were performed blind
with regard to animal genotype and were repeated by a second person to ensure no bias.
2.7: MTT Assay
Materials:
- dye solution (Promega)
- Solubilisation/stop solution (Promega)
- N,N-dimethylformamide
- Sodium dodecyl sulphate
- Acetic acid
- UV spectrometer
- Cell titre plate
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2.7 MTT Assay
We carried out MTT assays on our siRNA treated H441 and HMVEC cells to see if the
knock down of Mig-6 had any effect on cell viability.
The MTT assay is a cell viability assay in which cell permeable MTT (3-(4,5Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), usually a yellow colour is reduced
to purple formazan precipitate in living cells. Since the enzymes (reductases) that catalyse
formazan formation from MTT are only active in living cells, the amount of formazan formed
can be used as a measure of cell viability.Since formazan is insoluble in water, a
solubilisation solution containing DMFO, SDS and Acetic acid is used to dissolve the
formazan prior to measuring the absorbance at 570nm. MTT assays were performed on
siRNA treated H441 and HMVEC-L in 24-well plates following standard protocols as a
measure of cell viability following siRNA treatment. Following siRNA treatment, 75 µl of
dye solution (Promega, Madison, MI) was directly added to each well. After incubation at
37oC for 4 hours, 500 µl of solubilisation solution (Promega) was added and mixed well.
Absorbances at 570nm of the contents of the well were recorded and levels compared
between siRNA treated and untreated cells.
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2.8: Analysis of H441 cell line for mutated Mig-6
Materials:
-

TOPO TA cloning kit (Invitrogen)

-

OneShot E.coli cells (Invitrogen)

-

LB Broth from LB broth base powder (Invitrogen)

-

LB agar plates from LB agar powder (Invitrogen)

-

X-gal (Invitrogen)

-

Ampicillin (Invitrogen)

-

Agarose (Fisher Scientific)

-

5x TBE
o 53g Tris base (Fisher Scientific)
o 27.5g boric acid (Fisher Scientific)
o 20ml of 0.5M EDTA (Fisher Scientific)
o Make up to 1L with water

-

Blue loading dye (Promega)

-

0.5mg/ml Ethidium bromide (Sigma)

-

Power supply

-

Agarose gel electrophoresis tank

-

Microwave

-

Conical flask

-

10x high fidelity PCR buffer (Invitrogen)

-

dNTP mix (Invitrogen)

-

50mM MgCl2 (Invitrogen)

-

Primers:
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o Mig-6 code F&R (Invitrogen)
o Mig-6 code UTR F&R (Invitrogen)
-

Platinum high fidelity Taq (Invitrogen)

-

QIAprep Miniprep kit (QIAGEN)

-

Microcentrifuge

-

Microcentrifuge tubes

-

Tubes for LB broth

-

SOC medium (Invitrogen)

-

Peltier thermal cycler (MJ Research)

-

1kb DNA ladder (New England Biolabs)

-

EcoR1 restriction enzyme (Invitrogen)

-

EcoR1 restriction buffer (Invitrogen)

-

UV spectrometer

2.8: Analysis of H441 cell line for mutated Mig-6
We decided to sequence the Mig-6 gene in the H441 cell line we were using to ensure that it
contained no mutations. If the H441 was found to be mutated we wouldn’t be able to use it
for Mig-6 functional studies. To determine whether H441 cells carried a mutated Mig-6
allele, we performed a cloning reaction and sequenced all the products.
The cells were grown to a confluency of ~70% in the tissue culture core at Baylor College of
Medicine. RNA was isolated from cells and quantified as described in section 2.4. Isolated
RNA was reverse transcribed to cDNA as detailed in section 2.5.

55

2.8.1: Mig-6 PCR:
The cDNA was used as a template for amplification of the Mig-6 gene. Reaction volume was
50µl which was made up of the following components: 5µl 10x high fidelity PCR buffer, 1µl
10mM dNTP mix, 2µl 50mM MgCl2 , 0.2µl Platinum Taq High Fidelity, 0.5µl forward
primer(10µM), 0.5µl reverse primer (10µM), 3µl template DNA and 37.8µl water.
All primer sequences used in this experiment were designed using Vector NT1 Advance 10
software from Invitrogen. Primers were synthesised by Invitrogen and sequences are shown
in Table 2.2. Gene amplification consisted of an initial denaturation step where reaction
mixtures were incubated at 94oC for 2mins. This was followed by 30 cycles of denaturation at
94ºC for 30 seconds, annealing at 55oC for 30 seconds and extension at 68ºC for 2 minutes.
All amplifications were carried out in a Peltier thermal cycler (MJ Research)
Primer

Sequence 5’-3’

Product

Annealing

Magnesium

Size (bp)

Temperature

concentration

Mig-6
Code F

ATGTCAATAGCAGGAGTTGC
1386

Mig-6
Code R

5mM
55oC

CTAAGGAGAAACCACATAGGAT

5mM

Mig-6
5mM

Code UTR ACAGGTTTGGAGATGTCCCA
F

1466

55oC

Mig-6
Code UTR GAGAACCATTTGCTCCTATG

5mM

R

Table 2.2: Primer sequences, amplicon size, MgCl2 concentration and annealing temperature
for Mig-6 PCR reactions.
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Amplicons were visualised following electrophoresis using a 1% (w/v) agarose gel stained
with ethidium bromide (0.5 µg/ml) in a 1 X Tris-Borate-EDTA (TBE) buffer. A 1kb DNA
ladder (New England Biolabs ) was run alongside the samples in order to determine amplicon
size. The gel was run at a constant voltage (100V) until the bands had migrated about 1/2 to
2/3 of the distance to the end of the gel. The resulting bands (~1.4kb) were visualised and
then cut out (in order to gel purify the DNA).
Making the 1% agarose gel:
1g of low melting point agarose powder was dissolved in 100ml of 1X TBE buffer in a
conical flask and microwaved for approximately 90 seconds. When it was determined that the
agarose was fully dissolved, the flask was allowed to cool to ~60oC. Once the mixture had
cooled, 50µl of ethidium bromide was added and the flask swirled to mix. The agarose was
poured into the gel mould and allowed to set. Prior to loading, the comb was removed.
Samples were prepared for loading by the addition of 10µl of 5x loading dye to a 50µl
sample volume. The entire volume was loaded onto the gel alongside the 1kb ladder.

2.8.2 DNA Purification from agarose gel:
DNA was purified using the QIAEX II gel extraction kit from QIAGEN as follows: the band
was cut from the gel using a blade and its weight recorded (this determines how much of the
buffers to add in the purification process). The gel was dissolved in 450µl QX buffer and
15µl of resin was added. The mixture was vortexed and placed on a heating block at 40-50oC
for a total of ten minutes, vortexing the sample every two minutes. The sample was
centrifuged for ~15 seconds to pellet the resin, the supernatant was removed, 500µl of fresh
buffer was added and the mixture vortexed to resuspend the resin. Sample was centrifuged to
pellet the resin followed by adding 500µl of wash buffer, vortexing to resuspend the pellet
and centrifugation (~15 seconds). This wash step was then repeated. Following the second
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wash step, the supernatant was removed and the pellet air dried at room temperature until
most of the resin had turned white. 15µl of deionised water was added, the sample vortexed
and then incubated at 50oC for five minutes. Sample was centrifuged to pellet and entire
supernatant was transferred to a fresh tube. This purified DNA was used for the TOPO®
cloning reaction.

2.8.3 TOPO® Cloning Reaction
The following reaction mixture was prepared: 2µl of gel purified DNA, 1µl salt solution
(from the TOPO TA cloning kit), 2µl sterile deionised water and 1µl of TOPO vector
containing DNA ligase. The mixture was incubated for five minutes at room temperature and
then placed on ice in preparation for the transformation reaction.
Transformation procedure:
One vial of One Shot E. coli cells per transformation were thawed out. 2µl of the TOPO
cloning mixture prepared above was added to the E. coli and mixed. The reaction was
incubated on ice for 30 minutes followed by heat shock for 30-45 seconds at 42oC. 250µl of
room temperature S.O.C medium was added to the cells. This was incubated at 37oC for one
hour with shaking for the duration. 50µl of the transformation reaction was spread onto prewarmed LB agar plates containing x-gal and 100µg/ml ampicillin. Plates were incubated at
37oC overnight
2.8.4 Analysis of positive clones:
Following overnight culture, the LB plates were examined for evidence of positive clones
(white colonies). A positive clone is one which has taken up the vector with our DNA
inserted and hence the beta galactosidase gene in TOPO that ordinarily converts XGal into a
blue product is disrupted. Tubes were prepared each containing 3ml of LB broth with
100µg/ml ampicillin. Using a pipette tip, one colony was picked off the plate and this tip put
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into one of the tubes containing LB broth with ampicillin. The process was repeated for all
tubes. The tubes were incubated at 37oC overnight with constant shaking.

2.8.5 Plasmid Isolation and DNA purification:
The overnight broth cultures were spun down to obtain a pellet of bacterial cells and the
supernatant discarded. Plasmid DNA isolation purification was carried out using the QIAprep
Miniprep kit from QIAGEN. The bacterial pellet was resuspended in 250µl of buffer P1 and
transferred in a microcentrifuge tube. 250µl of buffer P2 was added and mixed by inverting
4-6 times. 350µl of buffer N3 was added and mixed by inversion (at this point the solution
should become cloudy). Samples were centrifuged at 10,000 rpm for ten minutes. The
supernatant was transferred to a QIAprep spin column. This was spun for ~60 seconds and
the flow through discarded. To wash the sample, 750µl of buffer PB was added and the tubes
spun at 13,000 rpm for 60 seconds. The flow through was once again discarded and tubes
centrifuged for a further 60 seconds. The column was placed into a microcentrifuge tube and
50µl of buffer EB was added, left to stand at room temperature for one minute and then
centrifuged for one minute to elute the DNA. The DNA was quantified by UV spectrometry
(OD260nm:OD280nm) and then three samples were sent for sequence analysis.
When a sequence result was received the sequence was compared to the known Mig-6 gene
sequence to see whether any mutations were present in the sequence from our H441 cells.
2.8.6 EcoRI digestion of plasmid:
Prior to sending the samples for sequence analysis, an EcoRI digestion was carried out to
ensure that the correct insert was present. 2µl of plasmid DNA, 0.5µl EcoRI, 1µl of buffer 3
and 6.5µl were mixed in a tube and incubated at 37oC for one hour. The samples were then
run on a 1% agarose gel and resulting bands were visualised on a UV transilluminator. For
samples with the correct insert present there were 3 different bands present (the Mig-6

59

sequence itself has an EcoRI site which is cut) bands are present at 4kb (the vector), 1kb and
0.5kb (the insert).

60

3. Results
To obtain our Mig-6d/d mice, Rosa26-Cre-ERT2 mice were crossed with Mig-6flox/flox (Mig6f/f) mice and the resulting Rosa26-Cre-ERT2; Mig-6flox/flox (Mig-6d/d) or Mig-6f/f mice (2
months old) were injected peritoneally with 1 mg of Tamoxifen for 5 days. These mice were
further maintained for 4 months before analysis. At six months old mice were sacrificed,
lung tissue harvested, mRNA extracted and real time quantitative PCR for Mig-6 was carried
out using 18s RNA as a control.
3.1 Real time PCR to show knock-out of Mig-6 in Mig-6 -/- mice and induced knock-out
of Mig-6 in Tamoxifen treated Cre+ d/d mice
The aim of this experiment was to test whether the Tamoxifen treatment had been successful
in inducing the knockout of Mig-6 in the Cre+ (Mig-6d/d) mice. We already know from
previous experiments in our lab that Mig-6 is involved at the developmental stages of the
lung (5) but we wanted to investigate what role, if any, Mig-6 has at the adult stage. The
administration of Tamoxifen to Mig-6f/f and Mig-6d/d mice at 2 months old is the first stage in
the process, if the Tamoxifen treatment is successful in knocking out Mig-6 in the Cre+ mice
then we can study Mig-6 in the adult mouse. As a large proportion of Mig-6-/- mice die before
reaching adulthood it is difficult to investigate Mig-6 beyond the neonatal period. Cre-ERT
is a functional Tamoxifen-dependent recombinase in cultured cells and transgenic mice. By
controlling the time point at which the target gene is excised using an inducible Cre
recombinase, it allows us to look at the role of the gene later in the developmental process or
in adult life as well as allowing tissue specific excision of the gene of interest (26).
The figure 3.1 below shows the relative expression of Mig-6 mRNA in our transgenic
Tamoxifen treated mice compared to a wild type strain.
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Significant differences were noted between the wild type mice and the knockout (-/-) mice as
well as the Tamoxifen treated Cre+ (d/d) mice. The Tamoxifen treated Cre- (f/f) mice had
Mig-6 levels significantly different to the knockout (-/-) and induced knockout mice.
Statistics were performed using One Way ANOVA with a Bonferroni post hoc test,

Relative Mig-6 mRNA

(*p<0.05).

+/+: wild type mice, -/-: Mig-6 knockout mice
f/f: Cre- mice, d/d: Cre+ mice

Figure 3.1: Quantitative real time PCR analysis of mRNA levels isolated from 6 month
old Mig-6+/+, Mig-6-/-, Mig-6f/f and Mig-6d/d lungs for expression of Mig-6
Once we successfully knocked out Mig-6 in these adult mice the next step was to carry out a
number of experiments looking at: General lung morphology, molecular markers, size of
alveolar spaces, sacrificing mice at different time points following the knockout of Mig-6.
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3.2 Comparison of the morphology of Mig-6f/f and Mig-6d/d adult mouse lungs
Mig-6 plays a role in lung development, highlighted by altered lung morphology/reduced
airway space in Mig-6-/- mice (5). We investigated whether lung morphology is altered when
Mig-6 is deleted in adult mice. To do this, we examined whether morphological differences
would be observed between the Mig-6f/f and Mig-6d/d mice. Mice were sacrificed at
approximately six months of age and the lung tissue harvested. This tissue was processed to
wax blocks in preparation for sectioning and staining. 4µm sections were cut using a
microtome and stained using a haematoxylin and eosin stain to show general morphology.
The H&E staining method involves application of the basic dye haematoxylin, which
colours basophilic structures with blue-purple hue, and alcohol-based acidic eosin, which
colours eosinophilic structures bright pink.

A

f/f

B

d/d

H&E

Figure 3.2
Panels A&B above show representative H&E stained lung sections from adult Mig-6f/f
and Mig-6d/d mice.
No morphological differences were observed between adult lungs obtained from Mig-6f/f and
Mig-6d/d mice upon H&E staining. As the lungs were fully formed in the adult mice before
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Mig-6 was knocked out it would seem that Mig-6 does not have any noticeable effect on lung
morphology after the initial development stage.
3.3 Adult Mig-6f/f and Mig-6d/d mice have normal airspaces
The next step after a general assessment of morphology of the lung sections by staining was
to take a series of sections stained using H&E to measure the size of the airspaces in our
RosaCreERT2 x Mig-6f/f mice. For comparison purposes we also measured sections from
wild type (Mig-6+/+) and Mig6 knock out (Mig-6-/-) mice. It has previously been shown in our
lab that Mig-6-/- mice have larger airspaces than Mig-6+/+ mice (5). We wanted to examine
our induced knock out (Mig-6d/d) mice to see if there was any effect on size of airspace. All
measurements were performed blind with respect to animal genotype.
Mig-6+/+ and Mig-6-/- measurements were in line with previous results from our lab and
showed that Mig-6-/- mice have significantly larger airspaces than wild type (Mig-6+/+) mice.
This indicates a role for Mig-6 in either the development of or maintenance of airspaces in
lung. Interestingly, a significant difference in size was noted between the Mig-6-/- mice and
all other genotypes examined, including our induced Mig-6 knockout model (Mig-6d/d). This
is strongly indicative that Mig-6 plays an important role in lung development but expression
of Mig-6 in the adult lung does not affect airway size. In line with this hypothesis, no
significant difference was noted between Mig-6+/+, Mig-6f/f or Mig-6d/d mice. Statistics were
performed using One Way ANOVA with a Bonferroni post hoc test (*p<0.05).
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Fig 3.3. Alveolar space measurements were carried out on wild type (Mig-6+/+) and knock out
(Mig-6-/-) mice as well as Tamoxifen treated Cre- (Mig-6f/f) and Cre+ (Mig-6d/d) mice. Mig-6-/mice have significantly increased airspaces while the Tamoxifen treated mice (both Mig-6f/f
and Mig-6d/d) have airspaces in line with wild type measurements (n=8).
3.4 Expression of Pulmonary Epithelial Cell markers in Mig-6-/- vs. Mig-6+/+
After measurement of the alveolar spaces in our mice we found no difference at the
morphological level. It was decided to then look at a number of different molecular markers
to investigate whether any differences would be apparent at the molecular level of the lung
epithelium in our Mig-6f/f vs., Mig-6d/d/ mice since there are noted differences between wild
type and Mig-6-/- mice.
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RNA was isolated from the lungs of wild type and Mig-6-/- mice in addition to the Mig-6f/f
and Mig-6d/d mice and the levels of the following molecular markers analysed using real time
PCR CCSP, T1 alpha, Muc5ac and SP-C. We analysed the marker levels in wild type and
knockout mice alongside our Tamoxifen treated mice (f/f and d/d). Although we observed no
phenotypic change in the Mig-6d/d mice we could not assume there would be no change at the
molecular level following the deletion of Mig-6 in adult mice so we investigated the
molecular markers.
3.4.1 CCSP levels in Mig-6+/+, Mig-6-/-, Mig-6f/f and Mig-6d/d mice
CCSP is Clara cell secretory protein and a significant difference is seen between Mig-6+/+ and
Mig-6-/- mice (5). CCSP is a protective lung protein which is believed to have antioxidant,
immunomodulatory and anticarcinogenic properties (60). CCSP is a developmental marker
involved in cellular differentiation in respiratory epithelium during development and early
life (61). Mig-6-/- mice have decreased CCSP levels (5).
Statistics were carried out on the data using One Way ANOVA with a Bonferroni post hoc
test, *p<0.05. Sample size was between five and nine mice for each group (n=5-9). We found
that there was a significant difference in the CCSP levels measured between our Mig-6f/f and
Mig-6d/d mice after deletion of Mig-6 with the treatment of Tamoxifen. Despite the high
variability between samples, this assay had sufficient numbers to show a significant decrease
in CCSP expression in Mig-6d/d mice compared with Mig-6f/f controls
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Figure 3.4: Quantitative real-time PCR analysis of mRNA levels isolated from adult Mig6+/+, Mig-6-/-, Mig-6f/f and Mig-6d/d lungs for the expression of Clara cell secretory protein
(CCSP)
3.4.2 T1 Alpha levels in Mig-6+/+, Mig-6-/-, Mig-6f/f and Mig-6d/d mice
T1 alpha levels increase in the lung throughout foetal development and is the first marker
gene known to be expressed in the adult lung solely by the alveolar type I epithelial cell (62).
As Mig-6 levels also increase and decrease at various stages in lung development we thought
it would be interesting to look at T1 alpha levels in our different mouse populations to see
whether the absence or presence of Mig-6 impacted on the level of T1 alpha present.
There is a significant difference in T1 alpha levels between Mig-6+/+ and Mig-6-/- mice with
Mig-6-/- having greatly reduced amounts compared with the wild type control. No significant
difference in T1 alpha was measured between f/f and d/d mice, nor did T1 alpha levels in
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these mice differ from the wild type levels measured. This is an interesting result to note as
T1 alpha levels were not affected when Mig-6 is knocked out at the adult stage of life while if
it is knocked out in the germline then the resulting Mig-6-/- mice. This would suggest that
Mig-6 and T1 alpha expression are both linked within the developmental process but
expression of T1 alpha is independent of expression of Mig-6 in fully developed adult lungs.
Statistics were performed using One Way ANOVA with a Bonferroni post hoc test, *p<0.05
(n=5-9).

*

Figure 3.5: Quantitative real-time PCR analysis of mRNA levels isolated from adult Mig6+/+, Mig-6-/-, Mig-6f/f and Mig-6d/d lungs for the expression of T1 alpha
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3.4.3 SP-C levels in Mig-6+/+, Mig-6-/-, Mig-6f/f and Mig-6d/d mice
SP-C is surfactant protein C and is found solely in the surfactant layer of the alveoli (63). It
has been reported to have the following three functions:
1: catalyze the formation of surface-associated three-dimensional structures at the air-liquid
Interface, 2: assist in the transfer of lipids from the monolayer to form stacked multi-layer
structures, and 3: act as protection against surfactant inactivation by serum proteins (64).
Mechanical strain has been shown to increase SP-C levels (65).
SP-C levels were analysed in our different transgenic mice and control wild type mice- Mig6+/+, Mig-6-/-, Mig-6f/f and Mig-6d/d. The only significant difference noted was between the
Mig-6-/- mice and all three other genotypes. Because the only difference in SP-C levels was
seen in mice where Mig-6 is knocked out prior to foetal development this may point to a link
between Mig-6 and SP-C in the developmental stages of life. It may be that Mig-6 has a
regulatory role and prevents overexpression of SP-C during development and when this
control is removed SP-C levels increase greatly. Alternatively, in the absence of Mig-6
expression the alveolar structures are under greater mechanical strain and that this may
indirectly lead to elevated SP-C expression. As there was no significant change in SP-C when
Mig-6 is knocked out post development it would appear that whatever role Mig-6 plays in
controlling SP-C levels is present only early in life.
Statistics were performed using One Way ANOVA with a Bonferroni post hoc test,
*p<0.05(n=5-9).
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Figure 3.6: Quantitative real-time PCR analysis of mRNA levels isolated from adult Mig6+/+, Mig-6-/-, Mig-6f/f and Mig-6d/d lungs for the expression of surfactant protein C (SP-C)

3.4.4 MUC5AC levels in Mig-6+/+, Mig-6-/-, Mig-6f/f and Mig-6d/d mice
MUC5AC is a gel-forming glycoprotein of gastric and respiratory tract epithelia that protects
the mucosa from infection and chemical damage by binding to inhaled microorganisms and
particles that are subsequently removed by the muco-cilary system (66). Hypersecretion of
mucins including MUC5AC is seen in many airway diseases and results in impairment of
muco-ciliary clearance and bacterial super infection (67).
In our measurements we found that wild type mice have low levels of mucin MUC5AC but in
knockout mice (Mig-6-/-) there is a dramatic increase in MUC5AC levels. The Tamoxifen
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treated Mig-6d/d and Mig-6f/f mice had MUC5AC levels similar to those of the wild type
mice. As levels of this mucin were not altered when Mig-6 was knocked out in the adult
phase of life it would appear that the lungs of Mig-6d/d mice are phenotypically normal and
not subject to excessive airway diseases (these results are for unchallenged mice). Statistics
were performed using One Way ANOVA with a Bonferroni post hoc test, *p<0.05(n=5-9).

Figure 3.7: Quantitative real-time PCR analysis of mRNA levels isolated from adult Mig6+/+, Mig-6-/-, Mig-6f/f and Mig-6d/d lungs for the expression of mucin 5AC (MUC5AC)
Overall result from measurement of molecular markers: in all cases there was a significant
difference in levels between wild type and knockout mice. The induced knockout mice had
similar levels of expression of MUC5AC, SP-C and T1alpha while CCSP levels in Mig-6d/d
mice were significantly different to wild type mice and Mig-6f/f controls.
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Knocking out Mig-6 in adult mice appears to have had no effect on phenotype or the
majority of molecular markers for normal lung function. This would suggest that the lungs in
adult Mig-6d/d mice are essentially normal even when Mig-6 expression is ablated using
Tamoxifen although our results indicate that CCSP expression moderately decreases in
Mig6d/d mice that are indicative of minor lung abnormalities or dysfunction. Therefore it
appears that Mig-6 exerts greater influence during the developmental stage of the lung. As
Mig-6 is a stress induced gene it may also be important in the lung’s response to
damage/hypoxia/other injury, in these cases we would hypothesise that a re-emergence of
developmental pathways could occur.
3.5 Silencing of Mig-6 expression in H441 epithelial lung cells using RNA interference.
The fact that Mig-6 is expressed in adult lungs points to the conclusion that it must serve
some purpose in adult mice but our results indicate that it does not appear to play a major role
in lung morphology or lung function. In order to look at the potential role(s) Mig-6 might
play in adult mice we used lung cell lines to investigate the effect of knocking down Mig-6
expression in different cell types (both epithelial and endothelial cells).
We decided to look at Mig-6 expression and function specifically in epithelial cells so we
used the H441 epithelial cell line for this purpose. The pulmonary epithelium plays a vital
role in the body through its role in gaseous exchange ensuring a constant supply of oxygen is
available to all cells throughout the body. In addition to its role in gaseous exchange the
pulmonary epithelium also has a number of other roles: It provides a protective barrier
between the host and the outside environment, contributes to the maintenance of lung fluid
balance, plays a role in the metabolism of endogenous mediators (68) and is capable of
regeneration, allowing normal cell turnover and restoration of airway and alveolar functions
after lung injury (69). Lung epithelium produces surfactant and several proteins which are
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important as part of the immune defences of the body (14). Because of these roles we were
interested in investigating what effect (if any) silencing Mig-6 expression in this specific cell
type would have.
These experiments would provide an in vitro model to investigate the role of Mig-6 in
epithelial cells. Half of our cells would be treated with siRNA with the other half treated with
a control siRNA that does not silence any known gene. Successful silencing of Mig-6
expression in the treated cells would allow us to harvest RNA and proteins from these cells to
examine what effects silencing of Mig-6 had on downstream elements of the signalling
pathway and thus gain further insight into what role Mig-6 has in adult lung epithelial cells.
The first step in looking at the role of Mig-6 in epithelial cells was to use siRNA to knock
down Mig-6. Previous experiments carried out in my lab using different concentrations of
siRNA showed 50nm to be a sufficient concentration to silence Mig-6 expression. Following
successful knock down of Mig-6 in this cell type the goal was to look at various elements of
downstream signalling pathways to see if removing Mig-6 has an effect. Mig-6 is a known
negative regulator of EGFR (70, 71) so we chose to look initially at signalling from the
EGFR.
The graph below (figure 3.8) shows the result of real time quantitative PCR (qPCR) analysis
on our siRNA treated and untreated H441 epithelial cells. RNA was extracted from the cells
as detailed in the Methods (section 2.4) and converted to mRNA. Real time PCR was carried
out for Mig-6 levels with 18s ribosomal RNA as a control. Significant difference was noted
in Mig-6 expression when cells were treated with Mig-6 siRNA compared with cells treated
with either no siRNA or siControl. No significant difference was noted between the cells
treated with siControl and the cells not treated with siRNA indicating that the decrease in
Mig-6 expression was due to the specific RNA interference activity of our siRNA. The

73

success of this experiment allowed us to continue our experiments and look at the effect that
this silencing of Mig-6 has on elements of the EGF signalling pathway.
Statistics were performed using One Way ANOVA with a Bonferroni post hoc test, (p<0.05).

1.6
Relative Mig-6 mRNA

1.4
1.2
1
0.8
0.6
0.4
0.2
0
no siRNA

siControl

siMig-6

Figure 3.8: Real time quantitative PCR to show successful knock-down of Mig-6 in H441
cells using 50nm siRNA
3.6 Silencing Mig-6 expression in HMVEC endothelial lung cells using RNA
interference
Endothelial cells play an important role in the lung as the cells which line the capillaries that
surround the alveoli in a network of blood vessels. As branching of the airways occurs in the
developmental stages each new bud is surrounded by a network of endothelial cells. It is
likely that Mig-6 also plays a role in regulating endothelial lung cell function; therefore we
chose to look at the role of Mig-6 in endothelial cells using the Human Microvascular
Endothelial Cells (HMVEC) cell line as our model.
The aim was to successfully silence Mig-6 in HMVEC cells using the same method as for the
epithelial cells. We planned to measure the same elements of the signalling pathway as in the
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epithelial cells and see if there were any similarities or differences in the effect knocking
down Mig-6 has on epithelial cells vs. endothelial cells.
The graph below shows the result of real time quantitative PCR analysis on our siRNA
treated and untreated endothelial cells. RNA was extracted from the cells as detailed in
section 2.4 and converted to mRNA. Real time PCR was carried out for Mig-6 levels with
18s ribosomal RNA as a control. Significant difference was noted between the cells treated
with Mig-6 siRNA and cells treated with either no siRNA or siControl. No significant
difference was noted between the cells treated with siControl and the cells not treated with
siRNA. Statistics were performed using One Way ANOVA with a Bonferroni post hoc test,
p<0.05.

Figure 3.9: Real time quantitative PCR showing successful knockdown of Mig-6 in
endothelial cells using 50nm siRNA. Levels of Mig-6 mRNA were compared in cells treated
with control siRNA, Mig-6 siRNA and untreated cells.
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3.7 Knockdown of Mig-6 leads to changes in cell proliferation: MTT assay
EGF signalling is involved in development of the lung and can activate downstream
signalling, Ras-PI3K/Akt and Ras/MAPK and cross-talk with other growth factors such as
TGF-β1 and HGF signalling which are all important in lung development (5). As Mig-6 plays
a role in the EGF signalling pathway it is plausible to hypothesise that if Mig-6 is altered or
silenced it may have an effect on the cells in which we silenced Mig-6 expression and the
function of Mig-6 in these cells might be established on the basis of silencing the expression
of Mig-6 using RNA interference. Moreover, Mig-6 deletion affects lung morphology during
development which may be regulated by increased cell proliferation / cell death due to Mig-6
expression.
We carried out a cell viability (MTT) assay to look at whether knocking down Mig-6 in our
epithelial cells and endothelial cells has any effect on cell viability and if so would both cell
types be affected in the same way or differently.
The MTT assay is a cell viability assay in which MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide), usually a yellow colour is reduced to purple formazan in
living cells. Since formazan is insoluble in water, a solubilisation solution containing DMFO,
SDS and Acetic acid is used to dissolve the formazan prior to measuring the absorbance at
570nm. Since the enzymes (reductases) that catalyse formazan formation from MTT are only
active in living cells, the amount of formazan formed can be used as a measure of living cells
(72). By looking at this type of assay we can see in vitro how cellular proliferation is affected
and get some idea of how different cell types would be affected by lack of Mig-6 in vivo.
Increased numbers of viable cells may indicate increased proliferation while a decrease in
viable cells may be an indication that knocking down Mig-6 leads to increased apoptosis or
decreased cellular proliferation. Results in Figure 3.10 below show that following
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knockdown of Mig-6 in the epithelial cells, there was a significant increase in the amount of
viable cells present when the MTT assay was performed which may point to increased
cellular proliferation or cell survival in this cell type. The opposite pattern was observed in
the endothelial cells with significantly decreased numbers of viable cells present following
knock down of Mig-6 by siRNA treatment. This may suggest that lack of Mig-6 in
endothelial cells leads to increased apoptosis or decreased cellular proliferation.
Statistics were performed using One Way ANOVA with a Bonferroni post hoc test, *p<0.05.

Epithelial Cells

Endothelial Cells

*

*

Figure 3.10: Results of MTT (cell viability) assay in H441 epithelial cells and HMVEC
endothelial cells showing increased levels of viable epithelial cells and decreased levels of
endothelial cells following treatment with 50nm siRNA
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3.8 Analysis of H441 cell line for mutated Mig-6
To ensure that the H441 epithelial cell line we were using did not contain any mutations in its
Mig-6 gene, we chose to sequence Mig-6 expressed by this cell line. It was important that no
mutations were present as we were using this cell line for a large number of our experiments
and should there be any mutations in its Mig-6 then our data would prove to be compromised.
To investigate our H441 cells we isolated RNA and amplified the Mig-6 sequence using
primers designed in house. We carried out a cloning reaction and sent the products for
sequencing. Analysis of the sequencing results showed that no mutations were present in the
Mig-6 gene in our H441 cell line.
H441 cells were cultured and the RNA isolated once the cells were at ~70% confluency. RTPCR was performed followed by Mig-6 PCR. Two sets of primers were used in the Mig-6
PCR- Mig-6 code and Mig-6 UTR. Mig-6 code is used to amplify only the coding region of
Mig-6 while Mig-6 code UTR also amplifies the untranslated region. The Mig-6 code UTR
therefore is a larger size as it incorporates both the translated and untranslated regions.
PCR product was run on a 1% agarose gel and photographed as follows:

1

2

3

1. Mig‐6 code UTR
2. Mig‐6 code
3. DNA ladder
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2 kb
1.5 kb
1 kb

Fig 3.11 Shows the result of the Mig-6 PCR. Lanes 1 & 2 shows the band produced using the
Mig-6 specific primers designed in house at ~1.5Kb and lane 3 shows the DNA ladder loaded
on the gel.
3.8.1 ECOR I digestion of plasmids
Prior to sending our clones for sequencing we carried out a digestion using ECORI to prove
that the clones we were sending contained the correct insert. We firstly carried out our
cloning reaction using a TOPO TA Cloning® Kit with pCR®2.1-TOPO® as our vector.
Sequencing results showed no mutations in the Mig-6 sequence of our H441 cells.
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4kb

1kb

0.5kb

Fig 3.12 shows the results of ECOR I digestion of the plasmids. The bands at 4 kb are the
vector whilst the bands at 1kb and 0.5kb are the Mig-6 sequence (the sequence itself contains
an ECOR I site so we get three bands when a digestion has been successful).
Lane 1: 1kb DNA ladder
Lanes 2-15: plasmids 1 to 14
3.9 Western blot analysis of siRNA treated and untreated cells
The aim of our procedures was to look at the proteins involved in the EGF signalling pathway
and ascertain whether their levels were altered when we silenced Mig-6 using siRNA
treatment. We were also interested in looking at the involvement of Mig-6 in the HGF
signalling pathway. It is already known that Mig-6 has a negative effect on HGF/Met-induced
cell migration. In addition to this is has previously demonstrated that Mig06 expression is
induced by HGF stimulation (73).
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3.9.1 HGF Induction of Mig-6 in H441 and NHBE cells
This experiment was designed to look at the effect of HGF on cells where Mig-6 had been
knocked out using siRNA. 40ng/ml HGF (hepatocyte growth factor) was administered for
varying amounts of time and proteins isolated for Western blot analysis. The hypothesis was
that if Mig-6 is involved in HGF signalling pathways then levels of Mig-6 proteins should
change once HGF has been administered to the cells. We used H441 cell line as our epithelial
cell model but also used NHBE (normal human bronchial epithelial) cells in our experiments
so we would have data from both an epithelial cell line and from primary epithelial cells.
HGF Induction of Mig-6 in H441 cells:
We were unable to obtain any data for actin as a control so the densitometry analysis in this
case will be a crude look at the changes occurring in this experiment assuming that the
amount of protein loaded into each well was equal. We used the 0 min time point as a
baseline to compare our other values to. An initial two-fold increase was observed at the 15
min timepoint. At 30mins post HGF administration, Mig-6 dropped to about ½ that of the
initial baseline level. At 2hrs post administration, mig-6 levels were ~3times that of the initial
level and further increased to 4 times baseline by the 4 hour mark.
The administration of 40ng/ml HGF appears to have a stimulatory effect on the production of
Mig-6 in H441 cells. Without an Actin loading control, we cannot normalize for the
variability in the amount of protein loaded into each lane. The experiment would need to be
repeated using our optimised Western blot protocol ensuring an Actin or other protein control
is included to more accurately assess how Mig-6 levels are affected upon HGF
administration.
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Fig 3.13a Shows the changes in Mig-6 levels in H441 epithelial cells observed at different

Protein Expression
(arbitrary units)

time points post administration of 40ng/ml HGF (hepatocyte growth factor)

Time post HGF administration
Figure 3.13b Densitometry analysis of western blot (fig 3.13a)
HGF Induction of Mig-6 in NHBE cells
Analysis of the Western blot by densitometry was carried out in order to look at what effects
administration of HGF would have on different protein levels in NHBE cells. We normalized
Mig-6 and EGFR expression using Actin as our control for equal protein loading.
Analysis showed little change in EGFR expression following treatment with HGF (as
expected since HGF does not bind to EGFR) whereas changes in Mig-6 levels were clearly
evident. Mig-6 expression quickly increased in expression and seemed to plateau after about
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30 minutes to 1 hour.Mig-6 expression increased dramatically (~3 fold) between 15 minutes
and 30 minutes post HGF administration. This dropped slightly to 2 ½ times the initial level
at 1 hour before rising to almost four times the initial level at 2 hrs and dropping back to 2 ½
fold again at the four hour time-point.
This experiment would need to be repeated to see if this pattern would be repeated or not. It
would also be interesting to look at other elements of the HGF pathway to see what effects
administration of HGF would have on these and whether any of these elements is having any
influence on the Mig-6 pattern observed in NHBE cells.
0min

15min

30min

1h

2h

4h

Mig-6

EGFR
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Fig 3.14a Shows the changes in Mig-6 and EGFR levels in normal human bronchial
epithelial (NHBE) cells observed at different time points post administration of 40ng/ml HGF
using actin as a loading control
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Time post HGF administration
Figure 3.14b: densitometry analysis of fig. 3.14a
3.9.2 EGF Induction of Mig-6 in H441 and NHBE cells
As Mig-6 has been shown to be a negative regulator of EGFR we wanted to look at the effect
of administering 40ng/ml of EGF to siRNA treated cells. Following this we also planned to
look at the downstream elements of the EGF signalling pathway. First we established the
effects of EGF on Mig-6 expression in cells.
EGF Induction of Mig-6 in H441 cells:
Unfortunately, since we do not have an Actin control we cannot normalize our Mig-6
expression levels to the exact amount of protein loaded in each lane. However, since we
quantified the protein concentration in each sample and attempted to load equal amounts of
protein into each lane we can establish that expression of Mig-6 appears to be sensitive to
EGF.
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Fig 3.15a Shows the changes in Mig-6 levels in H441 cells observed at different time points

Protein Expression
(arbitrary units)

post administration of 40ng/ml EGF (epidermal growth factor)

Time post EGF administration
Figure 3.15b Analysis by densitometry showed that an initial decrease was observed post
EGF administration but by the 1 hour mark, Mig-6 levels began to steadily increase. By the 4
hour time-point a two fold increase in Mig-6 is clearly evident.
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EGF Induction of Mig-6 in NHBE cells
0min
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C
Fig 3.16a Shows the changes in Mig-6 and EGFR levels in normal human bronchial
epithelial (NHBE) cells observed at different time points post administration of 40ng/ml EGF
(epidermal growth factor). Blot B: Shows EGFR levels at several time points following the

Protein Expression
(arbitrary units)

administration of 40ng/ml EGF. C shows the Actin control blot.
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Time post EGF administration
Figure 3.16b Analysis of the blots in fig 3.16a show that over the duration of the experiment,
the levels of EGFR have remained relatively the same whilst the levels of Mig-6 have
increased and decreased at different time points. The blots were normalised to Actin to allow
for any loading differences.
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Levels of Mig-6 began to rise from the 15 min point onwards with a large decrease occurring
at 1 hour post EGF administration. This dip was then followed by a steady rise in levels at the
remaining time points.
3.9.3 p-Akt levels in H441 cells in the presence and absence of EGF

Fig 3.17a shows Western blot analysis for p-Akt in H441 cells treated with 50nm siRNA in

% p-Akt in presence of EGF
compared to absence of EGF

the absence and in the presence of EGF

450%
400%
350%
300%
250%
p‐Akt & EGF

200%

p‐Akt

150%
100%
50%
0%
Con siCon siMig‐6

Figure 3.17b Analysis by densitometry showed that in the presence of 40ng/ml EGF, there
was an increase in p-Akt levels in all our siRNA treated cells.
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This experiment was designed to look at some of the elements of the EGFR signalling
pathway in epithelial cells where Mig-6 has been knocked down. Half of the cells were
subjected to siRNA treatment alone while the other half were treated in the presence of EGF.
In the cells where not EGF was added it appears that there is an increase in p-Akt levels
where Mig-6 has been knocked down using siRNA compared to the control where Mig-6 is
expressed. In the cells where EGF has been administered, there appears to be no real
difference between the levels of p-Akt in the control and siRNA treated cells.
The above blot (figure 3.17a) shows that in the cells treated with 40ng/ml EGF there appears
to be increased p-Akt levels compared with the cells not treated with EGF.

The Western blot section of our experiments did not yield much data as we spent much of our
time attempting to optimise our protocols to obtain useable data. We tried a number of things
in order to optimise our protocol including:
1. Switching our washing buffer from PBST to TBST.
2. Changing our blocking buffer from 1% milk in PBST to 5% milk in TBST, also we
switched from blocking at room temperature for one hour to a brief rinse in the new
blocking buffer.
3. Altering the concentrations of both our primary and secondary antibodies and diluted
them in 5% milk in TBST instead of 1% PBST.
4. We reduced the length of our washing steps from ten minutes to eight minutes.
These changed yielded better blots and would allow our lab to be able to repeat our
experiments and yield useful data on the proteins involved in the signalling pathways of
interest. The optimisation of the Western blot protocol was successful at the end of my
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time in the lab but shown below (fig3.18) is an example of the result obtained using the
new western blot protocol.
In the experiment below we treated the H441 cells with siRNA for 72hrs as detailed in
section 2.1. After siRNA treatment we harvested RNA for real time PCR analysis and protein
for Western blot analysis. As figure 3.18 below shows we successfully knocked down Mig-6
expression. This is illustrated again by the Western blot images above confirming the reduced
expression of Mig6 in siRNA treated cells only.

Mig‐6

β‐Actin

No siRNA

siControl

siMig-6

Fig 3.18a Western blot showing silencing of Mig-6 in H441 epithelial cells using 50nm
siRNA

% Mig-6 Protein
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Figure 3.18b densitometry analysis of figure 3.18a indicated that there was a 99% decrease
in Mig-6 levels when cells were treated with 50nm Mig-6 siRNA.
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4. Discussion
Our lab was interested in studying the role of Mig-6 in the normal situation and in
pathological conditions. By understanding the normal role that this gene plays we can gain
greater insight to the processes that lead to disease when this gene is either deficient or
completely absent. We proposed to carry out a number of different experiments in order to
achieve our aims. Our studies were divided into animal studies and in vitro cell based studies.
Studies have previously been carried out to look at how Mig-6 is involved in the normal
development of the lung and what happens when it is absent. We chose to look at the role of
Mig-6 in an adult population of mice. An inducible knock out model was created for this
purpose by crossing Rosa26-Cre-ERT2 (74) mice with Mig-6

flox/flox

mice resulting in either

Rosa26-Cre-ERT2; Mig-6flox/flox (Mig-6d/d) or Mig-6flox/flox (Mig-6f/f) mice. Upon
administration of Tamoxifen to Mig-6d/d mice Mig-6 was knocked down. This provided us
with adult mice lacking the Mig-6 gene and afforded us the opportunity to look at any effects
that this would have on these mice, using the Mig-6f/f mice as a control.
Our in vitro studies looked at an epithelial cell line and an endothelial cell line. Using siRNA,
Mig-6 expression was successfully silenced in both cell types. In these cells we looked at cell
viability following Mig-6 silencing. We also intended to look at elements of the EGF
signalling pathway and how they are affected by silencing Mig-6 expression.
Our initial experiments focused on the inducible knock out model. Once the Tamoxifen
treated mice had reached six months in age (4 months post Tamoxifen treatment) they were
sacrificed and the lung tissue harvested. Some of the harvested tissue was processed to
paraffin wax blocks and set aside for histological staining. The rest of the tissues were used
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for molecular studies. mRNA was extracted and used for real time quantitative PCR analysis
for Mig-6, CCSP, T1-alpha, SP-C and Muc5ac using 18s rRNA as a control.
Figure 3.1 shows the results of the real time quantitative PCR analysis of Mig-6+/+, Mig-6-/-,
Mig-6f/f and Mig-6d/d mice for Mig-6 RNA. We expected that Tamoxifen treatment would
cause the ablation of Mig-6 in adult Mig-6d/d mice. Rosa26-Cre-ERT2 mice were crossed
with Mig-6 flox/flox (Mig-6f/f) mice resulting in our Mig-6d/d mice. As expected, administration
of Tamoxifen to both of these populations of mice resulted in the successful ablation of Mig6 in the Mig-6d/d mice while Mig-6 expression was similar to normal adult levels in the Mig6f/f control mice. In this important experiment to test our conditional knockout model, we
demonstrated that expression of Mig-6 was comparable between wild type mice and Mig-6f/f
mice and between Mig-6-/- mice and Mig-6d/d mice. Therefore, this allowed us to use our
inducible knockout model to study the effects that the loss of Mig-6 would have (if any) in
adult mice.
Comparison of the morphology of f/f and d/d adult mouse lungs
It has been shown previously in our lab that Mig-6-/- mice exhibit altered lung morphology
(increased alveolar spaces and altered septation compared with wild type mice (5). However,
Mig-6 expression is ablated from conception in Mig-6-/- mice which hinders our efforts to
elucidate the role of Mig-6 in adult mice. Therefore, we chose to carry out a set of
experiments to compare lung morphology in Tamoxifen treated Mig-6f/f and Mig-6d/d mice.
Lung sections from our Tamoxifen treated mice were stained using Haematoxylin and Eosin
to show general morphology. Both the Mig-6d/d and Mig-6f/f mice showed normal lung
morphology and no differences were noted between the two genotypes. Measurement of the
alveolar spaces of Mig-6+/+, Mig-6-/-, Mig-6f/f and Mig-6d/d mice showed that while the Mig-6/-

had significantly larger alveolar spaces, specific depletion of Mig-6 in adult mice (Mig-6d/d)
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using Tamoxifen did not lead to any significant differences in alveolar size when compared to
wild type mice and Mig-6f/f mice.
Results of the histological analysis shows that when Mig-6 is ablated in adult mice using
Tamoxifen, the lung tissue remains morphologically similar to the wild type untreated mice.
These mice were at the adult stage of life and therefore their lungs were fully formed before
treatment to induce ablation of Mig-6 commenced. Our results appear to indicate that once
lung development is complete, Mig-6 may not have any noticeable effect on lung
morphology.
Pulmonary markers-CCSP, SP-C, T1 alpha, Muc5ac
There is a significant difference in T1 alpha levels between Mig-6+/+ and Mig-6-/- mice with
Mig-6-/- having greatly reduced expression of T1 alpha in the lung (see Figure 3.5). No
significant difference in T1 alpha expression in the lung was measured between f/f and d/d
mice, nor did T1 alpha levels in these mice differ significantly from the wild type levels
measured.

This is an interesting result to note as T1 alpha levels were not affected when

Mig-6 is knocked out at the adult stage of life while if it is knocked out in the germline then
the resulting Mig-6-/- mice have significantly reduced T1 alpha levels, this may point to a
decrease in type I airway epithelial cells as T1 alpha is used as a marker for this cell type. Our
data indicate that Mig-6 and T1 alpha expression are both linked within the developmental
process and that defective lung development in Mig-6-/- mice may contribute to the
decreased expression of this important alveolar type I epithelial cell.
SP-C levels in Mig-6-f/f and Mig-6d/d mice are unchanged from those seen in wild type levels
while levels in Mig-6-/- mice are greatly elevated. Because the only difference in SP-C levels
was seen in mice where Mig-6 is knocked out prior to foetal development this may point to a
link between Mig-6 and SP-C in the developmental stages of life. It may be that Mig-6 has a
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regulatory role and prevents overexpression of SP-C during development and when this
control is removed SP-C levels increase greatly. It is interesting to note that SP-C expression
has been found to increase when mechanical strain in the lung is increased (65) SP-C can be
used as a marker for typ1 II epithelial cells so it may be that in mechanical strain on the lung,
type II airway epithelial cell expression is increased. Lung morphology has developed
normally in the Tamoxifen treated Mig-6d/d mice and no increase in SP-C was observed,
suggesting that Mig-6 expression does not directly control SP-C levels. However, SP-C is
greatly elevated in the lungs of Mig6-/- mice suggesting that the increased SP-C expression
observed here may be due to increased mechanical strain as a consequence of developmental
defects in the lung morphology of Mig6-/- mice. Further investigations would be needed to
confirm or disprove this hypothesis.
MUC5AC levels in Mig-6-f/f and Mig-6d/d mice are not significantly different to that of wild
type mice. The Mig-6-/- mice on the other hand had a dramatic increase in MUC5AC. This
would suggest that MUC5AC levels may be linked with Mig-6 at a developmental stage but
not once the lungs have been formed as in our Mig-6-f/f and Mig-6d/d mice. As previously
mentioned, MUC5AC levels have been seen to be increased in airway disease (75) while
decreased Mig-6 levels are often seen in airway disease. This might suggest that there could
be a regulatory link between Mig-6 and MUC5AC.
In the case of the CCSP measurements, it appears as though the Mig-6d/d group express about
half the levels of CCSP compared with the wild type and Mig-6f/f mice. However, there was a
large degree of variability noted in these measurements so despite obtaining significant
differences, we would need to repeat this experiment to increase our confidence in our data
for this marker. However, one must also consider the possibility that Mig-6 expression plays
a role in regulating some functions of Clara cells in adult mice. If CCSP expression is
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consistently decreased in Mig-6d/d mice, then further experimentation should be carried out to
determine the role of Mig-6 in promoting CCSP expression.
Measurement of the molecular markers in our different mouse genotypes provided some
interesting results. In all four cases there was a significant difference noted between wild type
and Mig-6 knockout mice. In all but the CCSP measurements, no significant difference was
noted between our two genotypes of Tamoxifen treated mice. These levels were also
comparable to the wild type measurements obtained at the same time. These data seem to
indicate that Mig-6 does not directly regulate the expression of SP-C, T1 alpha and
MUC5AC in adult mouse lung cells.
In repeating the experiment we would also increase the number of animals of each genotype
tested account for this variability and this would allow us to be more confident that our
results would accurately represent the genotypes in question.
In vitro cell studies
The next set of experiments was designed to allow us to look at the effect of Mig-6 in specific
cell types in vitro and gain a greater insight into the signalling pathways that are influenced
when Mig-6 is knocked out. We looked at an epithelial cell line and an endothelial cell line to
ascertain whether any differences would be noted when we knocked out Mig-6 in these cell
types or whether the same signalling pathways would be affected in both cell types.
The first step was to use RNA interference to knock out Mig-6 expression. This was
successfully achieved using a concentration of 50nm siRNA. RNA was extracted from the
treated cells and real time quantitative PCR analysis for Mig-6 showed that we were
successful in silencing Mig-6 expression in both cell lines (See Figure 3.8 and 3.9).
Following this we moved onto the next set of in vitro experiments. We carried out a cell
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viability assay to look at whether silencing Mig-6 expression would have any effect on the
viability of the cells. Interestingly, our results showed that the number of viable epithelial
cells increased following silencing of Mig-6 expression using siRNA while cell viability was
seen to decrease when Mig-6 expression was silenced in endothelial cells.
We hypothesised from these results that in an epithelial cell population, silencing Mig-6
expression may cause an increase in cellular proliferation which would explain the increase
in viable cells measured. Another potential reason for the increased viable cells could be that
in the absence of Mig-6, regular cell death does not occur at the same rate as normal resulting
in increased cellular survival.
A decrease in viable cells was observed when Mig-6 expression was silenced in endothelial
cells. This led us to hypothesise that there was increased apoptosis in this cell population or
that there was a decreased rate of cellular proliferation. To investigate this further we could
use imunohistochemical staining for cleaved caspase 3 to look at apoptosis.
This may be linked to the pathways affected when Mig-6 is removed and our next step was to
investigate these pathways by looking at various protein levels in cells where Mig-6 has been
silenced as well as cells where Mig-6 levels remain as normal. Because Mig-6 is known to be
involved in the EGF signalling pathway that was our initial focus to see how downstream
elements would be affected upon silencing of Mig-6 expression. Activation of the EGF
receptor results in activation of various downstream signalling cascades including the
RAS/ERK pathway, the PI3K/Akt pathway and the JAK/STAT pathway which coordinate to
promote cellular survival and proliferation (76).
Mig-6 has been shown to be a negative regulator of EGFR signalling (30) so when it is no
longer present then EGF receptor activation kinetics are prolonged and the above mentioned
pathways (Ras/Erk; PI-3K/Akt; and JAK/STAT) may be activated for longer than normal
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leading to changes in cellular survival. It was interesting to note that when Mig-6 was
silenced it had differing effects on the survival of epithelial cells and endothelial cells. To
understand potential reasons for this it was necessary to look at levels of the individual
components of each signalling pathway involved to see at which point in the signalling the
differences occurred.
HGF signalling has also been linked to Mig-6 which led us to decide to look at what effect
HGF signalling pathways would have on Mig-6 expression and related signalling pathways.
We intended to look and both EGF-dependent and HGF-dependent induction of Mig-6
expression in lung epithelial cells treated with siRNA alongside untreated cells. In particular,
we were interested in whether administration of either EGF or HGF would significantly
affect the levels of Mig-6 expression and if so how long it would take to occur. We used
H441 cells again as our epithelial cell line but this time we also used NHBE cells as a
primary epithelial cell line to gain data from both a cell line and primary human cells. In
addition to investigating expression of Mig-6, we also intended to look at levels of various
proteins following EGF/HGF administration using Western blot analysis. The protein levels
we were interested include: total Akt and activated phospho-Akt (p-Akt), total mTor and
activated p-mTor, total EGFR expression and activated p-EGFR.
Initially we experienced difficulty in getting our Western blot protocol to work sufficiently
and as a result spent a large amount of our time altering the protocol in an attempt to optimise
it. The changes (altering buffers, blocking solution, changing antibody concentration and
altering incubation times) yielded better blots and would allow our lab to be able to repeat our
experiments and yield useful data on the proteins involved in the signalling pathways of
interest. The optimisation of the Western blot protocol was successful at the end of my time
in the time in the lab. Had there been more time we would have carried out our planned
investigation of the proteins involved in the pathways I mentioned earlier. In addition to
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looking at the changes seen at the protein level, it would also be interesting to look at any
changes seen at the RNA level to obtain the full picture. From the limited data we obtained it
appears that administration of EGF to Mig-6 siRNA treated cells can cause an increase in the
Mig-6 protein levels between 1 and 4 hours post-administration of EGF. This experiment
would need to be repeated to ascertain whether this is truly the case.
Our results showed some interesting data which provides further routed of investigation of
the role of Mig-6. Of particular interest were the results of the in vitro studies which showed
differing effects on cell survival/proliferation when comparing lung epithelial and endothelial
cells. The next step would be to use our improved Western blot protocol to obtain more data
on the different proteins affected in both cell types following silencing of Mig-6. This would
lead to a greater understanding of how these cells are affected in vitro and perhaps lead to
further research into potential therapies to overcome the effects of a loss of Mig-6.
Future directions for this research:
As Mig-6 is a stress induced gene our lab is interested in looking at what happens when Mig6 is knocked out at the adult stage of life but this time exposing the animals to a stress (such
as cigarette smoke for example) and examining whether this would show different effects
than when we simply just knocked out Mig-6 in adult mice. In our experiments the lungs of
induced knockout mice appeared to remain normal so it would be of interest to investigate
whether the same would be true when the induced knockout mice were also exposed to stress.
Because of the differences noted between effects on siRNA treated epithelial and endothelial
cells, our lab is interested in pursuing this and looking in more detail at the role of Mig-6 in
both types of cells.
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This inducible knockout model would also be beneficial in studying the role of Mig-6
expression in cancer, especially in light of its putative role as a tumour suppressor (2).
By understanding the role that Mig-6 plays in the normal individual, we can gain a better
insight into what happens when Mig-6 is absent and where things go wrong at a molecular
level. This will enable the development of more treatment options and ways to overcome the
effects which result from the absence of Mig-6.
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